pedics Trauma entistry Orthopedics Den Dentistry Orthop

Literature List 2021

Trauma

Osteoarthritis TherapyOrthopedics

DentistrySpine

pine

Spine

Orthop

entistry

Den

pedics

Orthope

Traum

2

Explanation

Abbrev.: Meaning:

M MaterialScientific / Fundamental Research

P Preclinic / in-vitro and in-vivo study

DC Clinic – Dental / Oral and Maxillofacial Surgery

TC Clinic – Traumatology / Orthopedics

d Dentoalveolar and OMF surgery

t Trauma surgery

o Orthopedic surgery

s Spine surgery / neurosurgery

CERASORB® & CERACELL®

Dentistry . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 – 40

Orthopedics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 41 – 48

ScientificFundamentalsPreclinic . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 49 – 76

ScientificFundamentalsMaterialScientific . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 77 – 80

JEDER®

Dentistry . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 82 – 84

Curavisc®

Orthopedics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 86 – 91

stypro®

Dentistry . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 93 – 95

Orthopedics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 96

General Surgery .................................................................................................................................... 97 – 98

ScientificFundamentals . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 99

CO

NTE

NT

3

CO

NTEN

T

Dentistry2020 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4

2019 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6

2018 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7

2017 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7

2016 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9

2015 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10

2013 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11

2012 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12

2011. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13

2010 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14

2009 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15

2008 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17

2007 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18

2006 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19

2005 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23

2004 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 27

2003 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 30

2002 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 33

2001 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 34

2000 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 37

1999......................................................39

1998......................................................40

1997......................................................40

Orthopedics, Trauma & Spine2020 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 41

2017 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 41

2016 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 42

2015 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 43

2014 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 43

2013 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 44

2012 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 44

2009 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 45

2007 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 45

2006 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 46

2002 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 46

2001 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 47

1999 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 48

Scientific FundamentalsPreclinic / in-vitro and in-vivo study

2020 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 49

2019 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 51

2018 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 53

2017 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 55

2016 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 57

2015 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 58

2014 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 59

2013 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 60

2011. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 63

2010 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 64

2009 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 65

2008 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 67

2007 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 67

2006 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 68

2005 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 70

2004 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 71

2003 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 73

2002 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 75

2001 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 75

2000 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 76

Material Scientific / Fundamental Research

2020 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 77

2019 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 78

2009 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 78

2006 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 79

2005 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 79

2004 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 80

SF

CERASORB® & CERACELL®

DEN

TIST

RY

4

CERASORB® & CERACELL® – 2020Year Legend Literature Products

2020 DCd

Duarte F, Ramos C (2020):Mandibular dentigerous cyst – Enucleation and bone reconstruction.implants 2020, 4: 16-20.

CERASORB® M,CERASORB® Foam,Osgide®

Comment:

“Challenging case of a one stage decompression followed by cyst enucleation, tooth extraction and bone reconstruction of a mandibular dentigerous cyst using CERASORB® M, CERASORB® Foam and Osgide® resorbable membrane achieving bone regeneration of the cystic cavity as well as maintenance of nerve integrity.”

2020 DCd

Kozakiewicz M, Wach T (2020):New Oral Surgery Materials for Bone Reconstruction – A Comparison of Five Bone SubstituteMaterials for Dentoalveolar Augmentation.Materials (Basel), 2020 Jun 30;13(13):2935. doi: 10.3390/ma13132935.

CERASORB® Foam,CERASORB® M,Osbone®

Comment:

“Comparison of bone replacement materials for their ability to produce living bone at the place of their implantation using texture feature analyses of 2D X-ray images.Five bone replacement materials are compared (Osteovit®-porous collagen, CERASORB® Foam, Osbone®, Endobon®-deproteinized bovine-derived cancellous bone hydroxyapatite, and CERASORB® M). The observed structure in the radiological image of the implantation sites of bone substitute materials containing calcium phosphates obtains the characteristics of a living bone image after twelve months. Pure collagen material does not have enough mechanical endurance in bone regeneration sites. Collagen blended with synthetic tricalcium phosphate revealed slightly higher mechanical properties (CERASORB® Foam).”

2020 DCd

Plugmann P (2020):Einfach und sicher implantieren.2020, DZW 39, OI 3: 40-41.

CERASORB® M, EpiGuide®

Comment:

“Clinical case of ridge augmentation after tooth extraction in regio 32, 33, 43, 44 with CERASORB® M and EpiGuide® and insertion of four implants.”

DEN

TISTRY

5


2020 DCd

Wach T, Kozakiewicz M (2020):Fast- versus slow-resorbable calcium phosphate bone substitute materials – Texture analysis after 12 months of observation.Materials (Basel), 2020 Sep 1;13(17):3854. doi: 10.3390/ma13173854.

CERASORB® M

Comment:

“Texture evaluation of intraoral radiographs on the resorbability of β-tricalcium phosphate (β-TCP, CERASORB®) versus hydroxyapatite (HA, Endobon®) during regeneration to the jawbone. The study included 88 patients during the 12-month follow-up. HA restores the alveolar crest better but requires more time for recovery after 12 months of observation. β-TCP becomes more similar to the reference bone tissue and is a promising none substitute because it directs the structural alteration to vital bones.”

2020 DCd

Habibi Y, Sagheb Ka, Wentaschek S, Al-Nawas B, Sagheb K (2019):Ästhetische Zone effektiv gestalten.[Shape effectively the aesthetic zone.]Z Zahnärztl Implantol 2019; 35: 222-227.doi: 10.3238/ZZI.2019.0222−0227.ArticleinGerman.

CERASORB® Foam

Comment:

“Case description of alveolar ridge preservation and formation of stable peri-implant soft tissue in regio 12 after tooth extraction using autologous thrombocyte and fibrinconcentrate (PRF: Platelet-rich Fibrin) in combination with a β-tricalciumphosphatecollagen matrix (CERASORB® Foam).After 6 months insertion of implant and after 3 additional months final prosthethic. Article emphasizes the importance of the alveolar ridge preservation after tooth extraction and soft tissue quality (thickness and implant adherence) for optimal outcome. Without ridge preservation, loss in bone width by about 50% on average after 12 months will occur.”

DEN

TIST

RY

6


2019 DCd

Duarte F, Ramos C (2019):Protocolo Implacure® – Tratamento descontaminante e regenera-tive da peri-implantite. [The Implacure® protocol – decontamina-tion and regenerative treatment of peri-implantitis.]O Jornal Dentistry 59, February 2019, online publication in Por-tugese, Abstract in English.

CERASORB® M,Osgide®

Comment:

“The treatment of a peri-implantitis case with bone defect of 40% of the length of the implant involving the use of the Implacure® Protocol in combination with a physical decontamination technique, followed by bone regeneration using CERASORB® M.”

2019 DCd

Foitzik J (2019):Minimalinvasiver Sinuslift nach JEDER – ein Erfahrungsbericht.[Minimally invasive sinus lift according to JEDER – a case report.]Implantologie Journal 12, 2019.

CERASORB®

Paste, JEDER® System

Comment:

“The article describes the experience with JEDER® System for the transcrestal sinus lift in combination with CERASORB® Paste in about 60 cases within 2 years. One case described in more detail. On the basis of this experience, sinus floor elevation according to JEDER® can be recommended without restriction as a reliable minimally invasive method for bone augmentation in the upper jaw side tooth area. No side effects or complications are reported. A case of a multi-chambered maxillary sinus in region 26 with a clear bony septum and insufficient vertical bone for an implant insertion is presented.”

2019 DCd

Palm F, Rupp J, Götz W (2019): Experiences with a collagen composite in socket preservation. implants 2019, 4: 14-18.

CERASORB® Foam,CERASORB® M,stypro®

Comment:

“A split-mouth clinical study with 35 patients was designed to evaluate the performance of CERASORB® Foam in socket preservation procedures. As a comparative material, a gelatine haemostatic sponge (stypro®, curasan) was chosenowing to similarities in the application techniques of both products. The publication presents two cases out of the study; one case of a patient with after severe periodontal disease affecting the bone and another case of alveolar ridge preservation with five teeth extracted. The healing in the CERASORB® Foam group was as good as the healing in the stypro® group. Both materials stabilised the haematoma, which was very good for the healing process. However, the bone loss in the stypro® group was significantly higher than in the CERASORB® Foam group.”

DEN

TISTRY

7


2018 DCd

Duarte F, Thomas G (2018): Peri-implantitis therapy. Using resorbable bone replacement material. implants 4, 2018: 24-26.

CERASORB® M

Comment:

“Description of the authors’ preferred peri-implantitis treatment protocol using a biomimetic bone replacement material (CERASORB® M) and a resorbable collagen membrane.”

2018 DCd

Lorenz J, Barbeck M, Kirkpatrick CJ, Sader R, Lerner H, Ghanaati S (2018): Injectable bone substitute material on the basisofβ-TCPandhyaluronanachievescompletebone regeneration while undergoing nearly complete degradation. Int J Oral Maxillofac Implants. 2018 May/June;33(3):636–644. doi: 10.11607/jomi.6026. Epub 2018 Mar 15.

CERASORB® Paste

Comment:

“The regenerative potential and pathways of a new injectable bone substitute (IBS) material composed of beta-tricalcium phosphate (β-TCP) and hyaluronan were investigated for its application in alveolar bone regeneration within extraction sockets. In the prospective study CERASORB® Paste was implanted in 44 extraction sockets after removal of teeth. The paste contributed to an osteoconductive tissue reaction while undergoing a time-controlled degradation. Clinical and radiological follow-up investigation of the implants inserted in the regenerated area after at least one year revealed that the paste contributed to a long-term stable implantation bedfor dental implants.” “The IBS was convincing with its favorable handling and enabled the complete filling of the extraction sockets, successful, stable, and effective replacement of the extracted teeth.” “The bone substitute material contributed to new bone formation and a stable surrounding for dental implants with a favorable and gentle tissue reaction and almost complete biomaterial degradation.”


2017 DCd

Lerner H (2017): Augmentationanddefectfillinginoralsurgery.Amulticenter non-interventional study. implants 2017, 2: 26–30.

CERASORB® Paste, membranes, Osgide®, PTFEComment:

“The novel paste-like bone regeneration material CERASORB® Paste, based on small β-TCP granules and a hyaluronic acid matrix has proven its efficacy in the filling of smaller jaw defects under daily practice conditions, especially because of its good manageability.”

DEN

TIST

RY

8


2017 DCd

Ludwig A, Thomas G (2017): A Clinical Comparison. ß-tricalcium phosphate vs hydroxyapatite ceramics. [Ein klinischer Vergleich. Einsatz von ß-Tricalciumphosphat versus Hydroxylapatitkeramik.] implants 2017, 4: 38-41. Article in English. First published in: Implantologie Journal 2016, 11: 36-39. Article in German.

CERASORB® M,Osbone®

Comment:

“β-TCP offers advantages in the filling of cysts where the goal is called physiologic bone regeneration. For sinus-lifting both materials are well suited. In combination with lateral augmentation or in cases with bad bone quality (D3/D4) and/or two-step procedures hydroxyapatite should be preferred.”

2017 DCd

Miller RJ (2017): Vergleich von Knochenersatzmaterialien. Risiken und Vorzüge synthetischer und boviner Materialien. [Comparisonofbone-graftsubstitutes.Risksandbenefitsof synthetic and bovine derivate materials.] Implantologie Journal 2017, 1&2: 28-30. Article in German. First published in: implants 2016, 4: 30-32. Article in English.

CERASORB® M

Comment:

“CERASORB® M is highly resorbable and replaced by autogenous bone at a rapid rate. Also, it provides a higher stress bearing modulus from an increased density. Last but not least, there is no foreign-body reaction and no risk of transmitting prions – it is safe.”

2017 DCd

Schermer S (2017) From granules to foam. [Vom Granulat zum Foam.DieEntwicklungeinesβ-Tricalciumphosphat–Knochen-regenerationsmaterials in klinischen Beispielen.] implants 3, 2017: 28-32. Article in English. First published in: Dent Implantol 2016, 20 (5): 302-309. Article in German.

CERASORB® M,CERASORB® Foam, Epi-Guide

Comment:

“The clinical examples show that β-TCP embedded in a collagen matrix offers an easy application and protection of the Schneiderian membrane in sinus-lift procedures. CERASORB® Foam plays an important role in the overwhelming number of augmentative indications by rapid change to vital own bone by support of the collagen matrix.”

DEN

TISTRY

9


2016 DCd

Bilk D (2016): Alveolenmanagement – Vorgehen und Mehrwert für Praxis und Patient. [TeethridgeManagement–ApproachandBenefitforPracticeandPatient.] Dent Implantol, 20, 4, 228–231 (2016). Article in German.

CERASORB® Foam

Comment:

“CERASORB® Foam has proven its efficacy in the augmentation of a larger vestibular defect as well in sinus augmentation and alveolar ridge preservation.”

2016 DCd

Blem G (2016): Bestimmung der relativen Kieferknochendichte mittels digitalen Messverfahrens nach Defektauffüllungen mit β-TCPunterBerücksichtigungderklinischenVerläufe.[Determi-nation of the relative jawbone density by means of digital measur-ingmethodafterdefectfillingwithβ-TCPtakingintoaccounttheclinical course.] Dissertation, Medizinische Fakultät der Georg-August-Universität zu Göttingen, Germany 2016: 1-87. Text in German.

CERASORB® M

Comment:

“Retrospective determination of bone density after treatment with β-TCP in 411 defect cases with the following indications: root tip resections (n = 181), filling of alveolar ridge defects for socket preservation (n = 47), osteotomies (n = 34), cysts (n = 14) and augmentations in connection with implants (n = 135). Relative bone density compared to the surrounding healthy bone between 97% and 102% was achieved in the four study groups (root tip resection osteotomy, socket preservation, cysts) after five to eleven months of follow-up. High absorption rate of β-TCP was shown with the addition of autogenous spongiosa from the implant drilling shaft. Demographic data such as age, gender of the patient, localization of defects had no statistically significant influence on the measurement results of relative bone density, bone regeneration or complication rate.”

2016 DCd

Ludwig A, Thomas G (2016): Einsatzvonβ-TricalciumphosphatversusHydroxylapatitkeramik.Ein klinischer Vergleich. [On the Application of β-TricalciumphosphateversusHydroxyapatiteCeramics. A Clinical Comparison.] Implantologie Journal 2016, 11: 36–39. Article in German.

CERASORB® M, Osbone®

Comment:

“β-TCP offers advantages in the filling of cysts where the goal is called physiologic bone regeneration. For sinus-lifting both materials are well suited. In combination with lateral augmentation or in cases with bad bone quality (D3/D4) and/or two-step procedures hydroxyapatite should be preferred.”

DEN

TIST

RY

10


2016 DCd

Miller RJ (2016): Comparisonofbone-graftsubstitutes.Risksandbenefitsofsynthetic and bovine derivate materials. implants 2016, 4: 30–32.

CERASORB® M

Comment:

“CERASORB® M is highly resorbable and replaced by autogenous bone at a rapid rate. Also it provides a higher stress bearing modulus from an increased density. Last but not least, there is no foreign-body reaction and no risk of transmitting prions – it is safe.”

2016 DCd

Schermer S, Kumalic S (2016): VomGranulatzumFoam.DieEntwicklungeinesβ-Tricalcium-phosphat – Knochenregenerationsmaterials in klinischen Beispielen. [FromGranulestoFoam.TheDevelopmentofaβ-Tricalcium-phosphate Bone Regeneration Material in Clinical Cases.] Dent Implantol 2016, 20 (5): 302–309. Article in German.

CERASORB® M, CERASORB® Foam, Epi-Guide

Comment:

“The clinical examples show that β-TCP embedded in a collagen matrix offers an easy application and protection of the Schneiderian membrane in sinus-lift procedures. CERASORB® Foam plays an important role in the overwhelming number of augmentative indications by rapid change to vital own bone by support of the collagen matrix.”


2015 DCd

Lorenz J, Barbeck M, Schlee M, Lerner H, Teiler A, Sader R, GhanaatiS(2015):Anwendungsbeobachtungeinerβ-TCP-basierten Knochenersatzmaterialpaste.[ObservationStudyofabonesubstitutepastebasedonβ-TCP.]Implantologie Journal 2015: 6: 24–30. Article in German.

CERASORB® Paste

Comment:

“When placing dental implants three months after augmentation a bony regenerated implant site was found, which enabled a stable insertion of dental implants.”

DEN

TISTRY

11


2013 DCd

Daif ET (2013):Effect of a multiporous beta-tricalicum phosphate on bone density around dental implants inserted into fresh ex-traction sockets. J Oral Implantol. 2013 Jun;39(3):339-44. doi: 10.1563/AAID-JOI-D-11-00079. Epub 2011 Sep 26.

CERASORB® M

Comment:

“Twenty-eight patients (18 women and 10 men), indicated for extraction of their lower premolars and insertion of immediate dental implants, were included in this study. They were randomly divided into two equal groups (14 patients each). Group A received immediate dental implants without any filling material around the implants, while group B received a pure-phase multiporous β-TCP (CERASORB® M, 500–1000 μm) which was mixed with a sterile normal saline and gently packed into the bone gaps around the implants. In all cases, the width of bone defects at the coronal portion of the implants was larger than 2 mm.” “The statistical analysis of the collected data showed a significant increase in the bone density measurements from 3 to 6 months only in group B (P <.05).”

2013 DCd

Harel N, Moses O, Palti A, Ormianer Z (2013): Long-term results of implants immediately placed into extraction socketsgraftedwithβ-tricalciumphosphate:Aretrospectivestudy. J Oral Maxillofac Surg 2013, 71 (2): e63–e68.

CERASORB®

Comment:

“In a 10 year retrospective study the crestal bone loss around immediate implant placed in tricalcium phosphate [TCP] grafted extraction sockets was evaluated. The use of TCP [CERASORB®] as a grafting material during immediate implant placement allowed no bone loss in 72.1% of the implants, which was very similar to the nongrafted cases for which implants were placed in favourable conditions.”

2013 DCd

Kishore DT, Bandiwadekar T, Padma R, Debunath S, Profulla, ReddyA(2013):Evaluationofrelativeefficacyofβ-tricalciumphosphate with and without type I resorbable collagen membrane in periodontal infrabony defects: a clinical and radiographic study. J Contemp Dent Pract. 2013 Mar 1;14(2):193-201.

CERASORB®

Comment:

“20 sites from 10 patients showing bilateral infrabony defects were selected and randomly divided into experimental site A (CERASORB®) and experimental site B (CERASORB® and BioMend Extend™, a type I resorbable membrane) (split mouth design). Significant reduction in all clinical parameters was observed in both the groups (plaque index, gingival index, probing pocket depth, clinical attachment, level and gingival recession at 6 weeks, 3, 6 and 9 months). On comparison no statistical significance was observed between the two groups.”

DEN

TIST

RY

12


2013 DCd

Rahpeyma A, Khajehahmadi S, Hosseini VR (2013): Lateral ridge split and immediate implant placement in moderately resorbed alveolar ridges: How much is the added width? Dent Res J (Isfahan). 2013 Sep; 10 (5): 602–608.

CERASORB®

Comment:

“Twenty-five patients were managed with ridge splitting technique. CERASORB® was used to fill the intercortical space. The technique showed predictable outcomes. The waiting time between surgery and beginning of prosthodontic treatment could be reduced to 3 months.”

2013 DCd

Shalash MA, Rahman HA, Azim AA, Neemat AH, Hawary HE, Nasry SA (2013): Evaluation of horizontal ridge augmentation using beta tricalcium phosphate and demineralized bone matrix: A comparative study. J Clin Exp Dent. 2013 Dec 1;5(5):e253-9. doi: 10.4317/jced.51244. eCollection 2013 Dec 1.

CERASORB® M

Comment:

“Evaluation of the effectiveness of beta tricalcium phosphate (β-TCP/CERASORB® M) alone compared to β-TCP and Demineralized Bone Matrix (DBM) in regenerating localized horizontal maxillary alveolar ridge deficiencies prior to implant placement. 20 patients with horizontal maxillary ridge deficiencies; initial ridge width of ≤ 5mm. There was a statistically significant difference between the mean area percentage of mineralized bone between both groups where it was 40.1% (range: 27.76% – 66.29%) for group I and 68.96% (range: 60.07% – 87.33%) for group II. Group II showed morebone gain with a mean of 1.37 mm crestally and 2.44 mm apically. This difference however was not statistically significant.”


2012 DCd

Modina T (2012): Intellectualsystemofmodernβ-TCPmaterialsanditsroleinperiodontal surgery. Poster No. P0189. Poster presentation on EUROPERIO 7, 7th Conference of the European Federation of Periodontology, Vienna/Austria 6–9 June 2012. Abstract.

CERASORB®

Comment:

“Longstanding multicentre scientific and practical experience with CERASORB® gives grounds to its consideration as one of the materials having the intellectual and informative qualities (“life crystals”) that are capable of precipitating the bone regeneration process.”

DEN

TISTRY

13


2012 DCd

Kühl S, Götz H, Brochhausen C, Jakse N, Filippi A, d’Hoedt B, KreislerM(2012):Theinfluenceofsubstitutematerialsonbonedensity after maxillary sinus augmentation: amicrocomputed to-mography study. Int J Oral Maxillofac Implants. 2012 Nov-Dec;27(6):1541-6.

CERASORB®

Comment:

“The study evaluates whether adding bone substitute materials to autogenous particulated bone (PAB) might have an effect on the density of the grafted bone after maxillary sinus augmentation. Thirty healthy patients undergoing lateral antrostomy were included. Sinuses were augmented at random with PAB (n = 10) (control group); a mixture of PAB and beta-tricalcium phosphate (β-TCP (CERASORB® 1000 – 2000 μm)) (n = 10) (experimental group); or a mixture of PAB, β-TCP, and hydroxyapatite (HA) (Straumann® BoneCeramicTM, 500 to 1,000 pm) (n = 10) (experimental group). A sample of each graft material was obtained at time of maxillary sinus augmentation, and microcomputed tomography (μ-CT) analyses were performed at baseline and after 5 months. All groups showed increasing density values after a healing time of 5 months. Because of a high dropout rate, the sample size was too small to compare the groups statistically.”


2011 DCd

Khatiblou F (2011): Histologic and histometric evaluation of bovine cancellous bone and beta-tricalcium phosphate 45 months after grafting in maxillary sinus. J Oral Implantol. 2011 Dec;37(6):727-33. doi: 10.1563/AAID-JOI-D-10-00093. Epub 2010 Oct 13.

CERASORB®

Comment:

“Single case description comparing CERASORB® and bovine cancellous bone (BCB) chips in sinus lift and 45 months follow-up with biopsies taken. Both β-TCP and BCB were completely resorbed and replaced by new bone 45 months after grafting. Percentage of calcified bone, marrow and connective tissue were almost the same.”

DEN

TIST

RY

14


2010 DCd

Jang HY, Kim HC, Lee SC, Lee JY (2010): Choice of graft materi-alinrelationtomaxillarysinuswidthininternalsinusflooraug-mentation. J Oral Maxillofac Surg. 2010 Aug;68(8):1859-68. doi: 10.1016/j.joms.2009.09.093. Epub 2010 May 26.

CERASORB®,PRP

Comment:

“In a total of 57 patients, 100 implants were placed by 3 different sinus floor augmentation techniques (lateral approach technique, osteotome technique, sinus drill and osteotome technique). Postoperative cone-beam CT (CBCT) scans were performed and the arrival distance of grafts from lateral wall to medial wall at the apical end level of the implant in the maxillary sinus was measured. Autogenous bone versus CERASORB®.” “In the internal sinus floor augmentation, grafting materials with solely osteoconductive potential are to be used for narrow sinuses. For large sinuses, autogenous bone with osteogenic potential should be used; alternatively, the reflection of the medial wall by the lateral window technique is recommended.”

2010 DCd

Kebernik M, Palm F (2010): Die Sinusbodenelevation und ihre Risiken. [Sinusflooraugmentationanditsrisks.]Oralchirurgie Journal 2010, 1: 14–18. Article in German.

CERASORB® M

Comment:

“The application of autologous bone alone gives no advantage compared to a mixture of bone and bone regeneration material (CERASORB® M) regarding implant survival rate.”

2010 DCd

Soleymani Shayeste Y, Khorsand A, Mahvidy Zade S, Nasiri M (2010): Clinical and radiographic evaluation of pure beta-tricalcium phosphate and autogenous bone graft in treatment of two to three-walled periodontal defects. [Abstract in English]. J Dent Med-Tehran University of Medical Sciences 2010; 23 (3): 183–190.

CERASORB®

Comment:

“The aim of this double blind study was to compare the effect of CERASORB® with autogenous bone graft (A.B.G) in the treatment of 24 two to three wall periodontal defects with baseline and 3-month, 6-month and one-year follow up evaluations. Treatment with CERASORB® compared to A.B.G produced the same results of improvement. Thus, the use of CERASORB® can be suggested in treatment of infrabony periodontal defects.”

DEN

TISTRY

15


2009 DCd

Elmohandes WA (2009): Evaluation of CERASORB® M as a bone graft used for sinus lift and dental implant installation. Abstract No. O10.12 in: Abstracts of the 19th International Conference on Oral and Maxillofacial Surgery, Shanghai, China, 23–27 May, 2009. International Journal of Oral and Maxillofacial Surgery, May 2009, 38 (5): S. 499 von 397–608.

CERASORB® M

Comment:

“The X-ray revealed complete or nearly complete degradation of the beta-tricalcium phosphate granules with concurrent bone substitution in the majority of cases in 12 months post grafting. The implants showed good stability 12 months after installation.”

2009 DCd

Harnack L, Boedeker RH, Kurtulus I, Boehm S, Gonzales J, Meyle J (2009): Use of platelet-rich plasma in periodontal surgery – a prospective randomised double blind clinical trial. Clin Oral Investig. 2009 Jun; 13 (2): 179–187.

CERASORB®, PRP

Comment:

“22 patients showing contralateral intrabony defects were treated with β-TCP CERASORB® alone or in combination with PRP. β-TCP is a satisfactory graft material in periodontal surgery, even without PRP.”

2009 DCd

Horowitz RA, Mazor Z, Miller RJ, Krauser J, Prasad HS, Rohrer MD (2009): Clinical evaluation of alveolar ridge preservation with a β-tricalciumphosphatesocketgraft.Compendium;2009Dec;30(9): 588–603.

CERASORB®, barriers, membranes, PTFE

Comment:

“Clinical measurements showed preservation of alveolar width, and histologic analysis demonstrated both resorption of β-TCP (CERASORB®) and conversion to vital alveolar bone. These characteristics make this graft material ideal for use after tooth extraction in conventional and implant dentistry.”

2009 DCd

Horowitz RA, Rohrer MD, Prasad HS, Mazor Z (2009): Enhancing Extraction – Socket Therapy. The Journal of Implant & Advanced Clinical Dentistry. 2009 Sept; 1 (6): 47–59.

CERASORB® M, membranes, Epi-Guide, PTFEComment:

“The predictable formation of vital bone in the extraction sockets treated with β-TCP of this and other studies has led to 100% success rates in implant placement and loading.”

DEN

TIST

RY

16


2009 DCd

Meyer C, Chatelain B, Benarroch M, Garnie JF, Ricbourg B, Camponovo T (2009):Greffes sinusiennes massives par phosphate tricalcique. Résultats à long terme.[Massivesinus-liftprocedureswithβ-tricalciumphosphate: Long-term results].Rev Stomatol Chir Maxillofac. 2009 Apr; 110 (2): 69–75. Epub 2009 Jan 25. Article in French.

CERASORB®, PRP

Comment:

“In 20 patients a total number of 33 sinus lift procedures by means of β-TCP CERASORB® were performed. The mean postoperative follow-up was 4.5 years. The implant success rate was 97.6%.”

2009 DCd

Nitsch A, Gruber R, Daevers INC, Patyk A, Merten HA (2009): Sinusbodenaugmentationmitβ-Tricalciumphosphatundplättchenreichem Plasma.[Sinusfloorelevationwithβ-tricalciumphosphateandPlateletRich Plasma.]ZWR 2009, 118 (6): 276–287. Article in German.

CERASORB®, PRP

Comment:

“In 29 patients an augmentation of sinus maxillaris with β-TCP or β-TCP and PRP was performed. The histomorphologic findings showed a progredient hydrolytic β-TCP degradation and cellular resorption of the ceramic fragments. The addition of PRP showed no difference.”

2009 DCd

Tetsch J, Tetsch P, Lysek DA (2010): Long-term results after later-alandosteotometechniquesinusfloorelevation:aretrospectiveanalysis of 2190 implants over a time period of 15 years. Clin Oral Implants Res. 2010 May;21(5):497-503. doi: 10.1111/j.1600-0501.2008.01661.x.

CERASORB®

Comment:

“Retrospective analysis of 2190 implants over a time period of 15 years comparing lateral and osteotome technique in sinus floor elevation. 1207 implants (461 patients) were placed into sites, in which the sinus was augmented using the lateral approach (LSFE), and 983 implants (522 patients) in sites augmented with the osteotome technique. Bovine bone mineral (n = 1217), β-tricalcium phosphate (n = 126). In 12% of cases CERASORB® was used (when patients were refusing xenogenic material). The implant survival rate with respect to the augmentation material was given as 97.4% after 170 months for the bovine bone mineral (Bio-Oss) and 94.1% for β-tricalcium phosphate (TCP) (CERASORB®) after 91 months (but less patients). Looking at the implant survival rate, no significant difference could be observed statistically zbetween the two materials.”

DEN

TISTRY

17


2009 DCd

Waluga R (2009): Erfolgsbewertung der klinischen Anwendung von β-TrikalziumphosphatzuralloplastischenRekonstruktionknöcherner Defekte im Kiefer- und Gesichtsbereich. [Clinicalevaluationofβ-tricalciumphosphateinthetreatmentofmaxillofacial bone defects.]Dissertation, Medizinische Fakultät Charité – Universitätsmedizin Berlin, 2009: 1–65. Text in German.

CERASORB®,CERASORB® M

Comment:

“A good clinical result can be achieved in traumatic defects up to 4 cm³ in combination with stable osteosynthesis and in cystic defects up to 4 cm³ with sufficient soft tissue closure, even without the admixture of autologous spongiosa.”


2008 DCd

Beyrle B (2008): Die simultane Implantation mit Sinusliftoperation bei reduziertem Knochenangebot – eine retrospektive, klinische Studie. [Simultaneous implantation with sinus lift operation in reduced bone – a retrospective, clinical study.] Dissertation, Department für Zahnheilkunde der Medizinischen Fakultät der Universität Ulm, 2008: 1–111. Text in German.

CERASORB®, (membrane), (Epi-Guide)

Comment:

“The augmentation material CERASORB® showed very good results regarding the remodelling of the implant. The augmentation of the sinus with CERASORB® is to be preferred instead of the use as admixture or the sole use of autologous bone chips.”

2008 DCd

Knabe C, Koch C, Rack A, Stiller M (2008): Effect of beta-tricalcium phosphate particles with varying porosity onosteogenesisaftersinusflooraugmentationinhumans.Biomaterials 2008, 29: 2249–2258.

CERASORB®, CERASORB® M

Comment:

“2 groups of 10 patients each were treated with CERASORB® and CERASORB® M. After 6 months, bone formation and matrix mineralization were still actively progressing in the tissue surrounding the particles. In the CERASORB® M-group, bone formation and particle degradation had already reached a more advanced stage.”

DEN

TIST

RY

18


2008 DCd

Plenk H, Lederer J (2008): CERASORB®: Materialkundliche Grundlagen und klinisch-histomorphologische Erfahrungen.[CERASORB®: Material science and clinical-histomorphological experiences.] Zahn Krone, 2008, 5: 16–20. Article in German.


Comment:

“In both granulate forms of CERASORB®, a progredient growth of woven bone around and in particular in the granulates is to be seen (“creeping bony substitution”). Both CERASORB® granulates are appropriate bone substitutes which are replaced by own bone tissue in a unique way.”


2007 DCd

Bilk D (2007): CERASORB® M in Dental Surgery – Post-marketing surveillance study with 148 patients.EDI Journal 2007, 3 (4): 40–46.

CERASORB® M,membrane

Comment:

“Treatment assessments of the 148 patients performed after 3 and 6 months showed continuous decrease of radiographically visible granulate, so that most implants could be placed between 4 to 6 months. Handling, efficiency and healing of the bone substitute were also assessed as good and very good in the vast majority of cases.”

2007 DCd

Cramer A (2007): Sinuslift und enossale Implantation. Eine retrospektive Zehnjahresstudie. [Sinus elevation and endosseous implantation. A retrospective 10-years study.] Dissertation an der Klinik und Poliklinik für Mund-, Kiefer- und plastische Gesichtschirurgie, Hohe Medizinische Fakultät der Rheinischen Friedrich-Wilhelms-Universität Bonn, Germany, 2007: 1–94. URN: urn:nbn:de:hbz:5M-09647. Text in German.

CERASORB®, PRP,(membrane)

Comment:

“In 144 patients 213 sinus-lift operations were performed and 514 dental implants placed. The application of the synthetic phase-pure β-tricalcium phosphate CERASORB® as bone substitute leads to excellent results regarding the implant survival rate.”

DEN

TISTRY

19


2007 DCd

Waluga R, Voigt A, Adolphs N, Nelson K, Klein M (2007): Augmentation eines Unterkieferknochendefekts nach Alveolarkammdistraktion. Die Anwendung von β-Tricalciumphosphat(β-TCP).[Augmentation of a mandible defect after alveolar ridge distraction –useofβ-tricalciumphosphate(β-TCP).]Impl J 2007, 5: 28–32. Article in German.

CERASORB® M

Comment:

“In the context of a surveillance study, the use of β-TCP for filling a larger mandibula defect after distraction-osteogenesis is reported. Despite a defect volume of4–5 ccm, β-TCP could be used with a good result even without additional autologous spongiosa.”


2006 DCd

Bilk D (2006): A New Bioresorbable Membrane in Augmentation Surgery. Implants 2006, 1: 20–21.

CERASORB® M, PRP, membrane

Comment:

“A new bioresorbable membrane (INION) in combination with CERASORB® M and PRP enables the placement of implants after sinus augmentation, even in cases where the residual bone hight was to be considered borderline for single-stage procedure.”

2006 DCd

Bilk D (2006): Eine neue resorbierbare Membran. [A New Resorbable Membrane.] Implantologie Journal 2006, 1: 22–24. Article in German.

CERASORB® M, PRP, membrane

Comment:

“The augmentation was performed with a combination of CERASORB® M, fresh blood and PRP covered by the resorbable membrane INION. This procedure leads to good bone regeneration after 6 months.”

DEN

TIST

RY

20


2006 DCd

Cseplö K, Vaszilko M, Bogdan S, Barabas J, Suba Z, Szabo G (2006): Useofβ-tricalcium-phosphate(CERASORB®)tofilllargejawbone defects: a medium-term study.Poster presentation, XV. ALACIBU-Congress in Cancun/Mexico, 01 May 2006.

CERASORB®

Comment:

“17 large jawbone defects were filled with 3 – 10 g CERASORB® mixed with blood taken from the bone defect. After 36 – 60 months all bone defects healed uneventfully. CERASORB® was almost completely resorbed and new bone building had occurred.”

2006 DCd

DominiakM,ŁysiakK(2006):Ocenaskutecznościwybranejmetodyregeneracjikościzzastosowaniemmateriałuwszczepialnegowleczeniupoekstrakcyjnychubytkówkościwyrostkazębodołowego–badaniawstępne.[Evaluation of Effectiveness of Selected Guide Bone Regeneration Method with Usage Biomaterial in the Treatment of the Defects of Alveolar Process After Teeth Extractions – Preliminary Study.] Dent. Med. Probl. 2006, 43, 3: 368–378. Article in Polish. Abstract in English.

CERASORB®, barrier, membrane, PTFE

Comment:

“This study suggests that treatment of extraction sockets with biomaterial (CERASORB®) and barrier membranes (TefGen®) is valuable in preserving alveolar bone in extraction sockets and preventing alveolar ridge defects.“

2006 DCd

Horch HH, Pautke C (2006): Regeneration statt Reparation – Eine kritische Bewertung des autogenen Knochentransplantates als „Goldstandard” bei der rekonstruktiven Chirurgie im Kieferbereich.[Regeneration instead of reparation – A critical review of the autogenous bone transplant as “golden standard” of reconstructive oral surgery.] Mund-, Kiefer- und GesichtsChir. 2006, 10 (4): 213–220. Article in German.

CERASORB®

Comment:

“Due to the further development of modern bone substitute materials which reveal in part superior long-term results for special indications the routine use of autogenous bone has to be critically reviewed.”

DEN

TISTRY

21


2006 DCd

Horch HH, Sader R, Pautke C, Neff A, Deppe H, Kolk A (2006): Synthetic, pure-phase beta-tricalcium phosphate ceramic granules (CERASORB®) for bone regeneration in the reconstructive surgery of the jaws. Int. J. Oral Maxillofac. Surg. 2006, 35: 708–713.

CERASORB®

Comment:

“The aim of the study was to investigate the long-term effect of the ceramic β-TCP at different sites of alveolar recon-struction and to evaluate its properties in 152 patients up to 52 weeks postoperative. Complete radiological replacement of β-TCP by autologous bone was found after approximately 12 months, indicating its osteoconductive properties.”

2006 DCd

Ormianer Z, Palti A, Shifman A (2006): SurvivalofImmediatelyLoadedDentalImplantsinDeficientAlveolarBoneSitesAugmentedwithβ-TricalciumPhosphate.Implant Dentistry 2006, 15 (4): 395–403.

CERASORB®

Comment:

“In all cases, bone defects were filled with β-tricalcium phosphate (CERASORB®) and immediate loading was per-formed with the goal of improving implant survival. After up to 4 years of clinical follow-up 1039 implants (97%) survived.”

2006 DCd

Palm F (2006): CERASORB®M–anewsyntheticpure-phaseβ-TCPceramicmaterial in oral and maxillofacial surgery – An open study of121 patients. IMOI 2006, 3: 24–27.

CERASORB® M

Comment:

“The results of this evaluation show CERASORB® M to be an ideal synthetic material with a porosity concerning body’s own spongiosa, degradation in time and simultaneous formation of body’s own bone, which enables the placement of implants already after 4–6 months.”

2006 DCd

PrincG,BertM,IfiJC(2006):Utilisationdusubstitutosseuxβ-phosphatetricalcique(β-TCP).Résultats à 3 ans.Le Chirurgien-Dentiste De France No. 1250/1251. 23–30 Mars 2006: 29–32.

CERASORB®

Comment:

“From a study, which has been conducted with 72 patients, a number of 10 patients could be examined after 3 years. The results of the 3 years showed a good stability of all implants as well clinically as well radiologically.”

DEN

TIST

RY

22


2006 DCd

Schermer S (2006): Augmentation and Defect Reconstruction with a New Synthetic Pure-Phase Beta-Tricalcium Phosphate – Open trial in289 patients. EDI Journal – European Journal for Dental Implantology 2006, 1: 31–39.

CERASORB® M, membranes, Epi-Guide, PTFE

Comment:

“CERASORB® M is an ideal synthetic material for use in the dental practice which does not expose surgeons and pa-tients to the risk inherent in materials of biologic origin nor does it require extensive pre-procedure patient information.”

2006 DCd

Schermer S (2006): Augmentation und Defektrekonstruktion mit einer neuen synthetischen,phasenreinenβ-TCPKeramik(CERASORB® M). [Augmentation and Defect Reconstruction with a New Synthetic, Pure-phaseβ-TCPCeramic(CERASORB® M).] Implantologie Journal 2006, 10 (2): 36–44. Article in German.

CERASORB® M, membranes, Epi-Guide, PTFE

Comment:

“In an open evaluation with 289 patients CERASORB® M showed to be an ideal synthetic material with a porosity concerning body’s own spongiosa for use in the dental practice.”

2006 DCd

Schermer S (2006): Defektrekonstruktion mit alloplastischen Knochenersatzmaterialien – Implantation bei reduziertem und stark reduziertem Knochenangebot. [Defect Reconstruction with Alloplastic Bone Substitute Materials – Implantations in reduced and severely reduced Bone.] Oralchirurgie Journal 2006, 1: 22–26. Article in German.

CERASORB®, CERASORB® M, membranes, Epi-Guide, PTFE

Comment:

“With the β-TCP materials CERASORB® and CERASORB® M, materials with highest phase-purity are available, which proved their value in the daily practice as well in common situations as well in difficult indications.”

2006 DCd

Schermer S (2006): Einzeitige Sofort- oder zweizeitige Spät-Insertion von 3i-Implantaten in rekonstruierten oder zu rekonstruierenden Arealen. [Immediate or delayed insertion of 3i-implants in reconstructed or to be reconstructed areas] Implantologie Journal 2006, 4 (10):42–47. Article in German.

CERASORB®, CERASORB® M, membranes, Epi-Guide, PTFE

Comment:

“CERASORB®, CERASORB® M respectively, showed after 3 – 6 months regularly a good resorption and in relation to time and the individual situation of the patient a very good osseointegration of the dental implants.”

DEN

TISTRY

23


2006 DCd

Suba Z, Takacs D, Matusovits D, Barabas J, Fazekas A, Szabo G (2006):Maxillarysinusfloorgraftingwithβ-tricalciumphosphateinhumans: density and microarchitecture of the newly formed bone. Clin. Oral Impl. Res. 2006, 17: 102–108.

CERASORB®

Comment:

“In 17 edentulous patients, the maxilla sinus floor was extremely atrophied, which was surgically elevated bilaterally by insertion of CERASORB® or autogenous bone graft. After 6 months, the new bone density was not significantly different. The augmented sinus floor was strong and suitable for anchorage of dental implants.”

2006 DCd

Szabo G, Bogdan S, Suba Z, Martonffy K, Hrabak K, Barabas J (2006): FüllunggroßerKieferknochendefektemitβ-Tricalciumphosphat(CERASORB®): Eine Fünfjahresstudie. [Fillingoflargejawbonedefectswithβ-tricalciumphosphate(CERASORB®):Afive-yearstudy.]Z Oral Implant 2006, 4: 202–211. Article in German.

CERASORB®

Comment:

“14 patients with 18 large defects of a diameter over 4 cm were observed over 5 years. In all cases, the filling with pure β-TCP CERASORB® was sufficient for a complete biological remodelling.”


2005 DCd

Bilk D (2005): Vorhersehbare und sichere Knochenregeneration mit verschiedenenFormeneinesphasenreinenβ-Tricalciumphosphats.[Predictable and Safe Bone Regeneration with Different Forms of aPure-phaseβ-Tricalciumphosphate.]Dent Implantol 2005, 9 (7): 564–572. Article in German.

CERASORB®, CERASORB® M, membranes, Epi-Guide, PTFE, (PRP)

Comment:

“A procedure concerning the protocol forms an aug-mentation complex from the synthetic inorganic material with which even large bony defects can be treated success-fully and implants can be placed immediately or promptly.”

DEN

TIST

RY

24


2005 DCd

Hille R (2005): Alveolar Ridge Preservation: Knochenaufbau nach Extraktion. [Alveolar Ridge Preservation: Bone Regeneration after Extraction.]Implantologie Journal 2005, 1: 12–18. Article in German.

CERASORB®, barriers, membranes, Epi-Guide, PTFE

Comment:

“The resorption of the alveolar bone after extraction of teeth is considerably less due to simultaneous augmentation of the alveoli with CERASORB® and the use of non-resorbable (TefGen) or resorbable (Epi-Guide) membranes as barriers on the extraction alveolus. The tolerability of the described procedures and materials is clinically evaluated as good to very good. Thus, this method can be recommended if a maximum preservation of the alveolar bone is essential, particularly for prosthetic reconstructions or because of aesthetic reasons.”

2005 DCd

Hille R, Vollmer R (2005): Alveolar Ridge Preservation: Preserving and Building up the Bony Structures after Extraction.Implants – International Magazine of Oral Implantology, Vol. 6 2005, 1: 22–28.

CERASORB®, membranes, Epi-Guide, PTFE

Comment:

“In a field study it could be shown that after the application of CERASORB® and of an appropriate membrane technique the alveolar crest could be maintained.“

2005 DCd

Hoch T (2005): Klinische Anwendung von Knochenaufbaumaterial bei Implantation mit offener Einheilung.[Clinical Application of Bone Substitutes at Dental Implantation with open Wound Healing] Implantologie Journal 2005, 4: 6–8. Article in German.

CERASORB®, PRP, membranes, PTFE

Comment:

“CERASORB® used mixed with blood and in combination with PRP or different membranes proves to be a bone augmentation material which is easy to use and shows high compatibility as well as safety regarding bone quality in the augmentation area.”

2005 DCd

Motsonelidze NR, Okropiridze TV, Kapanadze RV (2005): [Usage of CERASORB® in Complex Treatment of Chronic Generalized Periodontitis (Clinical-Experimental Study)]. Georgian Medical News, DUP-General Collection, W1 GE454n, No. 1, Jan. 2005, 17–20. Article in Russian.

CERASORB®

Comment:

“CERASORB® was used in the treatment of chronic generalized periodontitis. After 18 months the bone regeneration, confirmed by radiography, was shown in 87.8% and only 60.1% in the control group. CERASORB® can be recommended for using in the clinical practice.”

DEN

TISTRY

25


2005 DCd

Palti A, Hermann F (2005): Die geschlossene Sinusbodenelevation. Eine retrospektiv-röntgenologische Studie auf der Basis von 204 Implantaten zur Beurteilung der Veränderung der erzielten Augmentationshöhe. [Closedsinusflooraugmentation.Aretrospectiveradiologicalstudy based on 204 implants to evaluate the change of the achieved augmentation height.] Z Oral Implant 2005, 1: 6–14. Article in German.

CERASORB®

Comment:

“Sinus floor elevation has been performed in 104 patients, radiological follow-up was up to 24 months. An aug-mentation height of 2–4 mm could be reached in 44.1%, of 4–6 mm in 35.3% of the patients. The survival rate of all controlled implants was 96.1% within 2 years.”

2005 DCd

Plenk H jr, Lederer J (2005): Histomorphologie der Knochenregeneration nach Sinusbodenaugmentation mit zwei Formen eines TCP-Granulates – ein Fallbericht. [Histomorphologyoftheboneregenerationaftersinusflooraugmentation with two different designs of TCP-granulates – A case report.] Z Oral Implant 2005, 1: 32–38. Article in German.


Comment:

“In a multiphase denture reconstruction CERASORB® and CERASORB® M were used in sinus floor elevation. After 4.5 months growth of new built bone was seen between the granules and on the outer and inner surface as well as a smooth transition of the granulate to matrix of woven bone tissue.”

2005 DCd

Reich R, Appel T, Martini M, Lückerath W (2005): Improvement of Implant Survival in Sinus Grafts by the Use of Alloplastic Bone Replacement Materials. 2nd World Congress on Regenerative Medicine, Leipzig, Germany, 2005.

CERASORB®

Comment:

“210 sinus grafts were performed in 188 patients and 494 implants placed in the region of interest. When used β-TCP alone or in combination with autologous bone implant survival rates were up to 98%. Resonance frequency analysis delivered identical osseointegration levels for these areas as obtained in implants placed in local D2 bone.”

DEN

TIST

RY

26


2005 DCd

Szabo G, Huys L, Coulthard P, Maiorana C, Garagiola U, Barabas J, Nemeth Z, Hrabak K, Suba Z (2005): A Prospective Multicenter Randomized Clinical Trial of AutogenousBoneVersusβ-TricalciumPhosphateGraftAloneforBilateral Sinus Elevation: Histologic and Histomorphometric Evaluation.Int J Oral Maxillofac Implants 2005, 20: 371–381.

CERASORB®

Comment:

“Bilateral sinus grafting was performed on 20 patients. CERASORB® only was used on the experimental side, and autogenous bone only on the control side. Histologically and histomorphometrically, there was no significant difference between CERASORB® and autogenous bone in terms of quantity and rate of ossification.”

2005 DCd

Szabo G, Barabas J, Hrabak K, Suba Z, Garagiola U, Kadar B (2005): AutologerKnochenversusβ-Tricalcium-Phosphatallein– Eine radiologische und histologische Evaluation. [Autologousboneversusβ-tricalciumphosphatealone– a radiological and histological evaluation.] Z Oral Implant 2005, 4 (1): 216–222. Article in German.

CERASORB®

Comment:

“Bilateral sinus grafting was performed simultaneously – β-TCP (CERASORB®) randomly on one side, autogenous bone on the other side. The implants were placed after 6 months: The formation of new bone was similar on both sides.”

2005 DCd

Szabo G, Barabas J, Nemeth Z, Hrabak K, Suba Z (2005): VergleichvonautologemKnochenmitβ-Tricalciumphosphatbeibilateralem Sinuslift.[Comparisonofautologousbonewithβ-tricalciumphosphateinbilateral sinus lift.]Implantologie Journal 2005, 6: 50–53. Article in German.

CERASORB®

Comment:

“The new bone production was similar on both sides. The difference between the two sides was not significant. These results support the view that β-TCP can be a satisfactory graft material even without the addition of autogenous bone.”

2005 DCd

Wainwright M (2005): Augmentation unter besonderer Berücksichtigung der Ästhetik. Zwei unterschiedliche Verfahren im Vergleich. [Augmentation in special consideration of aesthetics. Two different procedures in comparison.]Implantologie Journal 2005, 4: 18–21. Article in German.

CERASORB® M, membrane, PTFE

Comment:

“To achieve a perfect restoration, “ridge-preservation-technique” is performed with β-TCP CERASORB® M and a non-resorbable membrane (TefGen). The implants are placed after 4–5 months – after the loss of a single tooth as well as after the loss of a number of teeth in the front tooth region.”

DEN

TISTRY

27


2005 DCd

Zerbo IR, Bronckers AL, de Lange G, Burger EH (2005): Localisation of osteogenic and osteoclastic cells in porous β-tricalciumphosphateparticlesusedforhumanmaxillarysinusfloorelevation.Biomaterials 26 (2005): 1445–1451. doi:10.1016/j.biomaterials.2004.05.003.

CERASORB®

Comment:

“In conclusion, this study confirms the hypothesis based on our earlier work that the cells infiltrating around and within the TCP material are osteogenic. The data suggest that the mechanism of degradation of the material is likely to be due to chemical dissolution and that the role played by osteoclasts is only minor.”

2005 DCd

Zijderveld SA, Zerbo IR, van den Bergh JP, Schulten EA,ten Bruggenkate CM (2005):MaxillarySinusFloorAugmentationUsingaβ-TricalciumPhosphate (CERASORB®) Alone Compared to Autogenous BoneGrafts.Int J Oral Maxillofac Implants 2005, 20 (3): 432–440.

CERASORB®

Comment:

“The results of the present study show that the sinus floorelevation procedure with β-TCP appears to be a reliable twophase procedure. Within the one year of follow-up no implantlosses or failures had occurred.”


2004 DCd

Basa S, Varol A, Turker N (2004): Alternative Bone Expansion Technique for Immediate Placement of Implants in the Edentulous Posterior Mandibular Ridge: A Clinical Report. Int J Oral Maxillofac Implants 2004 Jul–Aug, 19 (4): 554–558.

CERASORB®, PRP

Comment:

“The split-crest surgical technique is a valid reconstructive procedure for sharp posterior mandibular ridges. If performed using platelet-rich plasma and CERASORB®, it can shorten the osseointegration period.”

DEN

TIST

RY

28


2004 DCd

Bilk D (2004): Die Implantatversorgung außergewöhnlicher Defektsituationen. [Implant placement in exceptional defect situations.]Implantologie Journal 2004, 2: 30–36. Article in German.

CERASORB®, membrane, PTFE

Comment:

“The case descriptions show that today with modern augmentation and membrane techniques (CERASORB®, TefGen®- membrane) it is possible to treat even extreme cases without putting too much strain on the patient but effective and suc-cessful, without additional and unnecessary risks by additional operations.”

2004 DCd

Broos B (2004): Unterstützende Maßnahmen beim internen Sinuslift zum Schutz der Kieferhöhlenschleimhaut (Schneidersche Membran). [Supporting measures to protect the Schneiderian membrane in internal sinus lift operations.]Implantologie Journal 2004, 7: 47–48. Article in German.

CERASORB®, stypro®

Comment:

“After the preparation of the Schneiderian membrane with special osteotomes a gelatine sponge (stypro®) is inserted followed by the augmentation with pure-phase β-tricalcium phosphate CERASORB®. This procedure protects the Schneiderian membrane and improves the healing process. No complications have been observed.”

2004 DCd

Hoch D (2004): Verkleinerung von Ohrradikaloperationshöhlen mit phasenreiner β-Trikalziumphosphatkeramik.[Reduction of radical ear surgery cavities with pure-phase β-tricalciumphosphate.]Dissertation, Ruhr-University Bochum, Germany 2004, 1–70. Text in German.

CERASORB®

Comment:

“The histologic specimen show a large zone of newly formed bone. In those areas, which are not filled with newly built bone so far, β-tricalcium phosphate CERASORB® has the function of a placeholder serving as a scaffold and guide rail for the bone regeneration. … 37 patients (86% success rate) were free of symptoms. Thus the aim of treatment was reached …”

2004 DCd

Hotz W (2004): Retrospektive Fallstudie zum Sinuslift mit CERASORB® und PRP. [Retrospective Case Study – Sinus Lift with CERASORB® and PRP.] Implantologie Journal 2004, 1: 20–27. Article in German.

CERASORB®, PRP, membranes

Comment:

“Augmentation with the bone regeneration material CERASORB®, with and without addition of PRP, is a convenient and reliable method for both the dental implantologist and his patients, where an adequate implant bed is created from vital autologous bone within a reasonable amount of time.”

DEN

TISTRY

29


2004 DCd

Horch HH, Sader R, Kolk A (2004): Synthetische, phasenreine Beta-Tricalciumphosphat-Keramik (CERASORB®) zur Knochenregeneration bei der rekonstruktiven Chirurgie der Kiefer – Eine klinische Langzeitstudie mit Literaturübersicht. [Synthetic, non-reactive beta-tricalcium phosphate-ceramic (CERASORB®) for bone regeneration in the reconstructive surgery of the jaws. A clinical long term study with review of literature.] Deutsche Zahnärztliche Zeitschrift 2004, 12: 680–686. Article in German.

CERASORB®

Comment:

“A complete replacement of β-TCP-ceramic by autogenic bone could be proven radiologically after approx. 12 months. Because of its universal usability and low complication rate synthetic, non-reactive β-TCP-ceramic presents as an excellent alternative also for bigger bone defects as a supplement to autogenic spongiosa transplants.”

2004 DCd

Ormianer Z, Palti A (2004): Dentinogenesis Imperfecta – ein seltener Fall aus der Praxis. Frühe Implantation zur Vermeidung von Knochenverlust. [Dentinogenesis Imperfecta – a rare case from the practice. Early implantation to avoid bone loss.] Implantologie Journal 2004, 2: 6–10. Article in German.

CERASORB®, PRP

Comment:

“Successful augmentation with β-TCP (CERASORB®) combined with blood and PRP. Four months later placing of implants. Excellent result.”

2004 DCd

Suba Z, Hrabak K, Huys L, Coulthard P, Maiorana C, Garagiola U, Szabo G (2004): [Histologic and histomorphometric study of the bone regeneration inducedbyβ-tricalciumphosphate.(Multicentricstudy).]Orvosi Hetilap 2004 Jul 4, 145 (27): 1431–1437. Article in Hungarian.

CERASORB®

Comment:

“After 6 months, insertion of the beta-tricalcium phosphate graft resulted in formation of stable bony bed apt to anchor of dental implants.”

2004 DCd

Velich N, Nemeth Z, Toth C, Szabo G (2004): Long-Term Results With Different Bone Substitutes Used for Sinus Floor Elevation.J Craniofac Surg 2004, 15 (1): 38–41.

CERASORB®

Comment:

“A study of the frequencies of failures (graft material resorption and implant loss) after 810 maxillary sinus elevations with various graft materials or their combinations was conducted. Concerning the rate of loss of implants, the most favourable results were achieved with β-TCP alone or together with autogenous bone.”

DEN

TIST

RY

30


2004 DCd

Velich N, Nemeth Z, Hrabak K, Suba Z, Szabo G (2004):Repair of Bony Defect With Combination Biomaterials.J Craniofac Surg 2004, 15 (1): 11–15.

CERASORB®, PRP

Comment:

“At one year after the intervention, the site of the augmentation with β-TCP was in all cases occupied by hard tissue of good quality. The speed of remodeling seemed to be the fastest when the mixture of β-TCP and PRP was used.”

2004 DCd

Zerbo IR, Zijderveld SA, de Boer A, Bronckers AL, de Lange G, ten Bruggenkate CM, Burger EH (2004): Histomorphometryofhumansinusflooraugmentationusingaporousβ-tricalciumphosphate:aprospectivestudy.Clin Oral Implant Res. 2004, 15 (6): 724–732.

CERASORB®

Comment:

“CERASORB® is an acceptable bone substitute material for augmentation of the maxillary sinus. Due to its osteoconductive but not osteoinductive properties the rate of bone formation is somewhat delayed in comparison to autologous bone.”


2003 DCd

Böhm S, Kurtulus I, Gonzales J, Meyle J (2003): Effect of PRP on early wound healing in intrabony defects. Poster Presentation AAP 2003 San Francisco (Annual Meeting American Academy of Periodontology).

CERASORB®, PRP

Comment:

“The addition of PRP to the graft material seems to have a positive influence on the early wound healing after regenerative access flap surgery in intrabony defects.”

2003 DCd

Braun A, Appel T, Frentzen M (2003): Endodontic and surgical treatment of a geminated maxillary incisor.Int Endod J. 2003 May, 36 (5): 380–386.

CERASORB®

Comment:

“... the extraction socket was filled with β-TCP ceramic (CERASORB®). Radiographs taken … after 6 months showed no periodontal or periapical lesions. No signs of external resorption were identified.”

DEN

TISTRY

31


2003 DCd

Engelke W, Schwarzwäller W, Behnsen A, Jacobs HG (2003): Subantroscopic Laterobasal Sinus Floor Augmentation (SALSA): An Up-to-5-Year Clinical Study. JOMI The International Journal of Oral & Maxillofacial Implants 2003, 18 (1): 135–143.

CERASORB®

Comment:

“118 sinus augmentations have been performed on 83 patients using particulate alloplastic augmentation material (tricalcium phosphate) with various amounts of autogenous bone and blood. Mean augmentation height was 8.6 mm.”

2003 DCdt

Foitzik C, Staus H (2003): Le Fort I Osteotomy in Atrophied Maxilla and Bone Regeneration WithPure-Phaseβ-TricalciumPhosphateandPRP.Implant Dentistry 2003, 12 (2): 132–139.

CERASORB®, PRP, membranes

Comment:

“The pure-phase β-Tricalciumphosphate CERASORB® together with autogenous bone at a ratio of 4:1, in combination with patients’ own PRP for a vertical augmentation of completely atrophied maxillae, resulted in an advancement of 14 to 16 mm. After a period of 8 months the β-TCP was completely resorbed and the X-ray control showed no residual granules in the defect sites.”

2003 DCd

Moro G, Casini V, Bastieri A (2003): [Use of Platelet-rich Plasma in Major Maxillary Sinus Augmentation.]Minerva Stomatologica 2003, 52 (6): 267–271. Article in Italian.

CERASORB®, PRP

Comment:

“Major augmentation of the maxillary sinus was performed with a mixture of β-TCP (CERASORB®), PRP, and autologous bone tissue. All patients were successfully treated with formation of high quality bone tissue, which subsequently enabled optimal osseointegration of the implants inserted. In consequence the surgical trauma undergone by the patient is markedly reduced.”

2003 DCd

Reich RH (2003): Systemabhängige Steigerung von Implantat-Überlebensraten nach Sinuslift – retrospektive Analyse an 211 Fällen. [System related increase of implantation survival rates after sinus lift retrospective analysis in 211 cases.] Lecture, 15th DGI-Annual Meeting in Göttingen/Germany November 2003. Abstract in German.

CERASORB®

Comment:

“Examination of implant survival rates in augmented sinus lift areas in 211 cases: Hip spongiosa and hip spongiosa + CERASORB® and hip spongiosa + Ceros HA® were used as augmentation material. Only at implants inserted in CERASORB® there was no loss of implants.”

DEN

TIST

RY

32


2003 DCd

Schiroli G, Chiaramondia M (2003): Humanhistological4monthsfindingsusingacombinationofpure-phasebetatricalciumphosphate(β-TCP)andPlateletRichPlasma(PRP)chair-sidepreparationincomparisonwithβ-TCPalone, autogenous bone graft, DFDBA and Bio-Oss. Poster Presentation at the International Conference “Bone 2003”, NL-Maastricht, Oct. 2003.

CERASORB®, PRP

Comment:

“The histological evaluation of the biopsies displayed significantly more mature bone formation for the sites treated with β-TCP and PRP and β-TCP alone, followed by autogenous bone graft. The two sites filled with DFDBA and bovine bone graft displayed decreasing amounts of bone formation in the order of mentioning.”

2003 DCd

Trisi P, Rao W, Rebaudi A, Fiore P (2003): Histologic Effect of Pure-Phase Beta-Tricalcium Phosphate on BoneRegenerationinHumanArtificalJawboneDefects.The International Journal of Periodontics & Restorative Dentistry, 2003, 23 (1): 69–77.

CERASORB®

Comment:

“The pure β-TCP was resorbed simultaneously with new bone formation, without interference with the bone matrix formation. CERASORB® proved to be resorbable in 6 months without interference with the new bone matrix formation.”

2003 DCd

Velich N, Barabas J, Szabo G (2003): [About remodelling in connection with two cases of bone-substitution.]Fogorvosi Szemle 2003, 96 (3): 111–114. Article in Hungarian.

CERASORB®

Comment:

“The materials utilized for the reconstruction of facial bone defects must satisfy various requirements. Augmentation was carried out with β-TCP following the removal of a fibromyxoma. One year after the intervention, the site of the augmentation was occupied by hard tissue of good quality. The material satisfied the demands of transformation into bone (remodeling).”

2003 DCd

Velich N, Toth Ch, Szabo G (2003): [Clinical comparison of graft materials used for sinus elevation.] Fogorvosi Szemle 2003, 96 (1): 33–35. Article in Hungarian.

CERASORB®, PRP

Comment:

“In a survey of the causes of the lack of success (graft loss and implant failure) of sinus elevations with various graft materials or their combinations, CERASORB®/CERASORB® PRP had the best outcome.”

DEN

TISTRY

33


2002 DCd

Hoch T (2002): Knochenersatzmaterialien in der chirurgischen Zahnarztpraxis. [Bone regeneration materials in the dental surgery practice.] Implantologie Journal 2002, 6 (5): 20–25. Article in German.

CERASORB®, PRP, membranes, Epi-Guide, PTFEComment:

“CERASORB® mixed with blood and in combination with PRP or together with different membranes is easy to use in the daily practice and has a high degree of safety concerning the quality of bone in the later augmentation site. It is very well accepted by the patients especially as no second operation is needed to harvest autogenous bone and because of its biological compatibility.”

2002 DCd

Nemeth Z, Suba Z, Hrabak K, Barabas J, Szabo G (2002): [Autogenousboneversusβ-tricalciumphosphategraftaloneforbilateral sinus elevations (2 – 3D CT, histologic and histomorphometric evaluations).] Orvosi hetilap 2002, 143 (25): 1533–1538. Article in Hungarian.

CERASORB®

Comment:

“The unpleasant phenomena accompanying the removal of the patients own bone can be avoided through the use of a new synthetic material. Accordingly, when comparing the present results with the findings of other authors, β-tricalcium phosphate may be considered a good graft material even without autogenous bone.”

2002 DCd

Palti A, Hoch T (2002): A Concept for the Treatment of Various Dental Bone Defects. Implant Dentistry 2002, 11: 73–78.

CERASORB®

Comment:

“We have treated almost 1000 bony defect sites in267 patients with the bone regeneration material CERASORB®. Being resorbed simultaneously with the formation of new bone, it is completely replaced by the patient’s own vital bone within 6 to 12 months.”

2002 DCd

Palti A (2002): Bone Regeneration with CERASORB® – Restitutio ad Integrum. Dental Digest 2002.

CERASORB®, PRP, membranes, Epi-Guide, PTFE, Ti-Sytem

Comment:

“The pure-phase β-tricalcium phosphate CERASORB® fulfils all requirements which to be termed “bone regeneration material” instead of “bone substitute material”. It is resorbed simultaneously with the formation of new bone without any residue, thus providing the patient with own vital bone for implant insertion, the stabilization of adjacent teeth or just for aesthetic reasons.”

DEN

TIST

RY

34


2002 DCd

Palti A (2002): Regeneration knöcherner Strukturen durch augmentative Maßnahmen.[Regeneration of bony structures by augmentative measures.] Implantologie Journal 2002, 6 (5): 8–12. Article in German.

CERASORB®, (PRP), (membrane)

Comment:

“Six to twelve months after the use of CERASORB® the patient has vital bone at the implantation site. The time of regeneration depends on the patient’s individual metabolism and the careful following of the operation protocol by the dentist (freshen of the bone, mixing with blood, using a membrane).”


2001 DCd

Bilk D (2001): Augmentieren mit thrombozytenreichem Plasma (PRP) und CERASORB® – Eine erfolgreiche Kombination in der Implantologie. [CERASORB® and PRP – a Successful Combination in Augmentative Implantology.]Oralchirurgie Journal 2001, 2: 12–19. Article in German. (Translation in English available).

CERASORB®, PRP, membranes, PTFE

Comment:

“The cases presented in this article document the successful use of the CERASORB®-PRP-complex in sinus floor and alveolar crest augmentation. The resorption rate of CERASORB® is synchronous with bone remodeling. CERASORB® therefore is not a bone substitute but a bone regeneration material.”

2001 DCd

Bilk D (2001): SinusliftundmodifiziertesÜbertragungssystem.DieVersorgungeiner verkürzten Zahnreihe im rechten Oberkiefer mit Hilfe von zwei ITI-Implantaten. [Sinusliftandmodifiedtransfersystem.Thetreatmentofashortened row of teeth in the right maxilla using two ITI implants.] Starget 2001, 4: 18–19. Article in German (also available in English).

CERASORB®, (PRP)

Comment:

“It was possible to incorporate a denture after a period of only four months despite of only bone height of approx. 5 mm and an open sinus lift. This is considerably shorter than the times that have been usual hitherto with such operations.”

DEN

TISTRY

35


2001 DCd

Bilk D (2001): Synthetisches Knochenaufbaumaterial in Kombination mit autologen Wachstumsfaktoren und Stabilisierung durch eine Titanfolie – Kasuistiken. [Synthetic bone augmentation material in combination with autologous growth factors and stabilisation by a titanium foil – case reports.] Dent Implantol 2001, 5: 198–207. Article in German.

CERASORB®, PRP, membranes, Ti-System

Comment:

“Even larger defects can be regenerated successfully without the amendment of autologous bone with CERASORB®, a pure-phase β-TCP ceramic, patients own PRP and stabilization of the augmentation material with a titanium foil.”

2001 DCd

IfiJC,BertM,PrincG,SzaboG(2001):UtilisationduSubstitutOsseuxβ-PhosphateTricalcique.Étudepréliminaire. – À propos d’un matériau de comblement. Le Chirurgien-Dentiste De France No. 1055. 6 Dec 2001: 29–33.

CERASORB®

Comment:

“In 72 patients with different indications the transformation of the implanted β-TCP into bone was complete after 12 months. Load-bearing tissue had already developed after 4 – 6 months. The study showed that autologous bone is not necessary for sinus grafting or the filling of cysts: β-TCP alone is suitable for this purpose.”

2001 DCd

Iglhaut G (2001): Die Atrophie des Alveolarknochens nach Zahnextraktion verhindern.[To avoid the atrophy of the alveolar crest after teeth extraction.] DZW-Spezial 2001, 11: 28–33. Article in German.

CERASORB®, PRP

Comment:

“The combination of β-TCP CERASORB® and PRP forms an augmentation complex that regenerates vital bone at the defect site. The alveolar ridge preservation technique with CERASORB® and PRP should be used as standard treatment after teeth extraction.”

2001 DCd

Siervo S, Coraini C, Siervo P, Giardini R (2001): CERASORB® und PRP in der regenerativen parodontalen und implantatunterstützten Therapie.[CERASORB® and PRP in regenerative periodontal and implant-supported therapy.] Implantologie Journal 2001, 6: 49–58. Article in German.

CERASORB®, RPR, membranes, PTFE

Comment:

“The osteoconductive properties of CERASORB® associated to its resorption rate over time and the osteoinductive properties of PRP implement new bone formation.”

DEN

TIST

RY

36


2001 DCd

Schmedtmann NO (2001): Eine Methode zur sicheren und vorhersagbaren Knochenregeneration.[A method to obtain safe and predictable bone regeneration.] Dentale Implantologie 2001, 5: 260–267. Article in German.

CERASORB®, PRP, membrane, PTFE

Comment:

“Through the combination of phase pure β-tricalcium phosphate CERASORB® with autogenous thrombocyte concentrate PRP (platelet rich plasma), the regeneration of bone defects in the jaw region could be optimized and the algesia reduced.”

2001 DCd

Kisters GJ (2001): Knochenersatz und nicht resorbierbare Membranen. Klinische Anwendung von alloplastischen Knochenersatzmaterialien und mikroporösen, nicht resorbierbaren PTFE-Membranen. Teil 1 – GTR. [Bone replacement and non-resorbable membranes. Clinical use of alloplastic bone replacement material and micro-porous, non-resorbable membranes.] Oralchirurgie Journal 2001, 4: 28–36. Article in German.


Comment:

“In combination with TefGen membranes the bone regeneration material consisting of pure-phase β-TCP (CERASORB®) mixed with blood from the defect and autologous bone has an osteoconductive effect and is totally resorbed. The risk-free use, the osteoconductive effect of the material and the complete resorption are the essential advantages.”

2001 DCd

Szabo G, Suba Z, Hrabak K, Barabas J, Nemeth Z (2001): AutogenousBoneVersusβ-TricalciumPhosphateGraftAloneforBilateral Sinus Elevations (2- and 3-Dimensional Computed Tomographic, Histologic, and Histomorphometric Evaluations): Preliminary Results. Int J Oral Maxillofac Implants 2001: 16 (5): 681–692.

CERASORB®

Comment:

“Comparisons of the present results with the findings of other investigators demonstrated that β-tricalcium phosphate is a satisfactory graft material, even without autogenous bone.”

DEN

TISTRY

37


2001 DCd

Wiltfang J, Schlegel KA, Merten HA (2001): Klinische Ergebnisse nach Anwendung der resorbierbaren, phasenreinenβ-TricalciumphosphatkeramikCERASORB® im enossalen Lager. [Clinical results after application of resorbable, pure-phase β-tricalciumphosphateceramicCERASORB® in enossal bed.] ZWR 2001, 110 (9): 556–559. Article in German. (Translation in English available).

CERASORB®

Comment:

“CERASORB® proved to be suitable in the treatment of the described lesions. Bony substitution occurred after 6–7 months in lesions up to 2 ml. In larger defects (up to 7 ml) bone substitution occurred after 12 months.”

2001 DCd

Zerbo IR, Bronckers AL, de Lange GL, van Beek GJ, Burger EH (2001): Histology of human alveolar bone regeneration with a porous tricalcium phosphate.Clin Oral Implants Res. 2001, 12: 379–384.

CERASORB®

Comment:

“The data presented suggest that this graft material, possibly by virtue of its porosity and chemical nature, may be a suitable bone substitute that can biodegrade and be replaced by new mineralizing bone tissue.”


2000 DCd

Foitzik C (2000): Anwendung und Erfahrungen mit phasenreinem β-TrikalziumphosphatinderMund-Kiefer-Gesichtschirurgie.[Applicationandexperiencewithpurephaseβ-tricalcium-phosphate in oral and maxillo-facial surgery.] TraumaLinc 2000, 1: 74–80. Article in German.

CERASORB®

Comment:

“In oral and maxillo-facial surgery, bony defects can be filled safe and with favourable results with the bone augmentation material CERASORB®. Experiences with non- or purely resorbable hydroxyapatite ceramics were rather unfavourable in the long term.”

DEN

TIST

RY

38


2000 DCd

Kreusser B, Jakobs W (2000): Wenn der Knochen nicht gut genug ist. Chirurgische Konzepte zur Verbesserung des Implantatlagers. [If bone is not good enough. Surgical conceptions to improve the implant sites.]Implantologie Journal 2000, 4: 8–13. Article in German.


Comment:

“Different correctional procedures enable the surgeon to substitute insufficient bone support by means of one stage or two stage surgery. The insertion of dental implants will keep their outstanding ranking only if the different build-up techniques are performed safely and responsible. In most cases CERASORB®, a pure-phase β-TCP ceramic was successfully used.”

2000 DCd

Reinhardt C, Kreusser B (2000): Retrospektive Studie nach Implantation mit Sinuslift und CERASORB®-Augmentation. [Retrospective Study of Dental Implantation with Sinus Lift and CERASORB® Augmentation.]Dentale Implantologie 2000, 4: 18–26. Article in German.

CERASORB®

Comment:

“Thanks to its high biocompatibility and the fact that to some extent it forms a template for bone regeneration, β-tricalcium phosphate in the form of CERASORB® is in many respects at least in value to autologous bone. Similarly, the success rate of 99% (with 50 patients) ... using CERASORB® alone is comparable to that achieved with autologous bone. An additional benefit of this procedure is that it does not result in a second operation.

The osseointegration of the β-tricalcium phosphate was investigated histologically and radiologically. The rate of resorption of CERASORB® was found to be the same as the rate of local bone regeneration. After six months the reconstructed trabecular architecture was considered on the basis of histological criteria to be suitable for insertion of a dental implant.”

2000 DCd

Szucs A, Suba Z, Martonffy K, Hrabak K, Gyulai-Gaal S, Dori F, Szabo G (2000):[The value of beta-tricalcium-phosphate (CERASORB®) in pre-prosthetic surgery.]Fogorvosi szemle 2000, 93 (2): 45–52. Article in Hungarian.

CERASORB®

Comment:

“In 52 patients with different indications the transformation of the implanted β-TCP into bone was complete after 12 months. Load-bearing tissue had already developed after 4 – 6 months. Studies suggest that autologous bone is not necessary for sinus grafting or the filling of large cysts: CERASORB® alone is suitable for this purpose.”

DEN

TISTRY

39


1999 DCd

Foitzik C, Staus H (1999): Parodontale Defektauffüllung mit phasenreinem β-Trikalziumphosphat.[Treatmentofperiodontaldefectswithpure-phaseβ-tricalciumphosphate implant.]ZWR 1999, 6: 378–383. Article in German.

CERASORB®, (membranes)

Comment:

“Use of a combination of pure-phase β-tricalcium phosphate and resorbable membranes can lead to clinically favourable outcomes, even in high-risk procedures or where the risk of infection is high. Risks of immunological reactions and the transmission of pathogenes are not inherently associated with synthetic pure-phase β-TCP.”

1999 DCd

Foitzik C, Staus H (1999): Phasenreinesβ-TrikalziumphosphatzumKnochenersatzbeiparodontaler Indikation.[Pure-phaseβ-tricalciumphosphateforbonesubstitutioninperiodontal disease.]Die Quintessenz 1999, 50 (10): 1049–1058. Article in German.

CERASORB®, membranes, PTFE

Comment:

“Synthetic pure-phase β-tricalcium phosphate is of special interest among the available bone substitutes, as this material is fully resorbed and replaced by natural local bone within a reasonable period of time. The favourable clinical results with pure-phase β-TCP as bone substitute broaden the range of indications for treating periodontal bony defects.”

1999 DCd

Staus H, Foitzik C (1999): Implantatinsertion bei gleichzeitiger Augmentation des Kiefer-kammes.Fallbeschreibungenmitβ-Tricalciumphosphatkeramik.[Implant insertion and augmentation of the alveolar crest in a one stageoperation.Casestudieswithβ-tricalcium-phosphateceramic.] Implantologie Journal 1999, 4: 12–5. Article in German.

CERASORB®, (PTFE)

Comment:

“The disadvantage of transferring autogenous bone is obvious. The employment of a synthetic resorbable bone-replacing material (β-TCP, CERASORB®) and its complete substitution by endogenic bone will exclude the transfer of pathogenic germs and any precarious immunoreaction.”

DEN

TIST

RY

40


1998 DCd

Kreusser B (1998): AugmentationundSinusbodenelevationmitreinemβ-TCP:GuteErgebnisse auch ohne Beimengung autologer Spongiosa. [Augmentationandsinusfloorelevationwithpureβ-TCP:Goodresults even without adding autologous cancellous bone.] Die Zahnarztwoche (DZW) Spezial 1998; week 12: 22–24. Article in German.

CERASORB®

Comment:

“The use of CERASORB® only is a safe procedure for sinus lifts. The quality of the augmented bone seems to render the addition of autologous cancellous bone superfluous. The material helps to generate the quantity and quality of endogenous bone material that is necessary for placing implants.”


1997 DCd

Foitzik C, Stamm M (1997): Einsatzvonphasenreinemβ-TricalciumphosphatzurAuffüllungvon ossären Defekten – Biologische Materialvorteile und klinische Erfahrungen. [Theuseofsingle-phaseβ-Tricalciumphosphatetofillosseousdefects – Biological advantages and clinical practice.] Die Quintessenz, October 1997, 48 (10): 1365–1377, Reprint, Article in German.

CERASORB®

Comment:

“The pure-phase β-TCP CERASORB® has been used in 86 cases. After a follow-up period of 20 months, X-ray examination showed an improvement of the clinical findings in nearly all patients.”

1997 DCd

Stamm M, Foitzik C (1997): Sinusbodenelevation mit autologer Spongiosa und CERASORB®. Erste histologische und röntgenologische Untersuchungen. [Sinus Floor Elevation with autologous spongious bone and CERASORB®. First histologic and radiologic examinations.] Lecture on FIT, Frankfurt, July 19, 1997, Germany, Poster in German.

CERASORB®

Comment:

“The mixture of autologous spongious bone and pure-phase β-TCP granulate CERASORB® is a safe procedure for pre- and periimplantologic augmentation.”

OR

THO

PEDIC

S, TRA

UM

A & SPIN

E

41


2020 TCM o

Busch A, Herten M, Haversath M, Kaiser C, Brandau S, Jäger M (2020):Ceramic scaffolds in a vacuum suction handle for intraoperative stromal cell enrichment.Int J Mol Sci, 2020 Sep 2;21(17):6393. doi: 10.3390/ijms21176393.

CERASORB® M

Comment:

“A surgical vacuum suction handle was filled with either bone substitute granules (CERASORB® M) or cancellous allograft, both acting as a filter to harvest cell-tissue composites (CTC). The study investigated the osteopromotive potential of CTC trapped in the bone substitute filter material during surgical suction in 10 elective total hip and knee replacement surgeries. Mononuclear cells (MNC) were isolated from the CTC and investigated towards cell proliferation and colony forming unit (CFU) formation; mesenchymal stromal cells (MSCs) were examined for surface markers, and the presence of defined cytokines for stimulation of cell proliferation and differentiation. Relevant numbers of MSCs and cytokines qualified for bone regeneration were found in the allograft and CERASORB® M granules. No significant differences could be found in the capability to enrich MSCs and growth factors. Neither biomaterial-associated differences for the amount of MNC harvested nor variations in the stemness character of the cells (number of CFU) were found.”


2017 TC o

Rolvien T, Barvencik F, Klatte TO, Busse B, Hahn M, Rueger JM, Rupprecht M (2017): β-TCPbonesubstitutesintibialplateaudepressionfractures.The Knee 2017: 8 pages, http://dx.doi.org/10.1016/j.knee.2017.06.010. Article in Press.

CERASORB® M granules,block forms

Comment:

“This study with 52 patients illustrates that β-TCP blocks and/or granules combined with internal fixation represent an effective and safe treatment of displaced tibial plateau fractures with good functional recovery. β-TCP bone substitutes represent a promising alternative to autografts and allografts.”

DEN

TIST

RY

42


2017 TC t o

Gruber A (2017): Knochenersatz mit CERASORB® in der Orthopädischen Chirurgie, Unfallchirurgie und Handchirurgie. Langzeitbeobachtung über 10 Jahre. [Bone substitute with CERASORB® in orthopedic surgery, traumatology and hand surgery. A long-term observation over 10 years.] OUP 2017; 3:164–171. DOI 10.3238/oup.2017.0164–0171. Article in German. Reprint in English.


Comment:

“Monocentre prospective long-term study over 10 years with 106 cases with trauma, rheumatism, tumour indications in hand and foot surgery. In nearly all cases the long-term follow-up showed a complete osseointegration and resorption of CERASORB®. Over the course of 10 years the synthetic bone graft CERASORB® has proven to be an alternative to autologous spongiosa as bone void filler without allergic reactions or material-caused complications.”


2016 TCs

Daentzer D, Hübner WD (2016): Anwendung von CERASORB® Foam in der Wirbelsäulenchirurgie. [The use of CERASORB® Foam in spinal surgery.] Poster presentation. Meeting Abstract, Deutscher Kongress für Orthopädie und Unfallchirurgie (DKOU 2016) in Berlin, 25.–28.10.2016, Düsseldorf: German Medical Science GMS Publishing House; 2016. DocPO27-50. Abstract in German.

CERASORB® Foam, CERASORB®

Comment:

“CERASORB® Foam has proven itself in the field of lumbar spinal surgery and leads reliable in combination with autologous bone material to spondylodesis.”

2016 TCs

Daentzer D, Hübner WD (2016): Anwendung von CERASORB® Foam in der Wirbelsäulenchirurgie. [The use of CERASORB® Foam in spinal surgery.] OUP 2016; 4: 242–248. DOI 10.3238/oup.2016.0242–248. Article in German. Reprint in English.

CERASORB® Foam, CERASORB®

Comment:

“Clinically, pain situation and functional outcome showed statistically significant improvement after 3 and 12 months. During follow-up resorption of posterolateral attached bone substitute material increased radiologically as well as new bone regeneration.”

OR

THO

PEDIC

S, TRA

UM

A & SPIN

E

43


2015 TCto

Breil-Wirth A, Jerosch J (2015): Keramisches Knochenersatzmaterial in der Orthopädie und Unfallchirurgie: Anwendung von CERASORB® Foam – (Poster P50). [Ceramic Bone Substitute in Orthopedics and Trauma surgery: On the Application of CERASORB® Foam.] Poster presentation, 63rd Annual Congress of “Norddeutsche Orthopäden- und Unfallchirurgenvereinigung e. V. (NOUV)”, Hamburg, Germany, June 18–20, 2015. Poster in German.

CERASORB® Foam

Comment:

“The results confirm CERASORB® Foam as well tolerated and easy to handle bone regeneration material. Regarding resorption and new built bone good to very good results could be shown.”


2014 TCto

Breil-Wirth A., Jerosch J. (2014): Anwendung von CERASORB® Foam in der Orthopädie – eine prospektive Studie. [Application of CERASORB® Foam in orthopaedics – a prospective trial.] OUP, 2014; 10: 608–615. DOI 10.3238/oup.2014.0608–615. Article in German. Reprint in English.

CERASORB® Foam

Comment:

“28 patients with different orthopedic indications were included in this study and evaluated after 12 months. The results approved CERASORB® Foam as a well working bone replacement material, which is easy to use and to apply.”

2014 TCto

Gruber AAJ (2014): Knochenersatz mit CERASORB® in der orthopädischen Chirurgie, Unfallchirurgie und Handchirurgie – Eine 10-Jahresstudie. [Bone substitute with CERASORB® in orthopedic surgery, traumatology and hand surgery – A 10-years long-term study.] Poster presentation [P40], 62th Annual Meeting of „Vereinigung Süddeutscher Orthopäden und Unfallchirurgen e.V. (VSOU)”, Baden-Baden, Germany, May 1–3, 2014, Abstract in German.


Comment:

“Prospective long-term study with 106 cases with the following indications: trauma, rheumatism, tumour in hand and foot surgery. There were no allergic reactions or material-caused complications. In nearly all cases the long-term follow-up showed a complete osseointegration and resorption of CERASORB®. Over the course of 10 years the synthetic bone graft CERASORB® has proven to be an alternative to autologous spongiosa as bone void filler.”

OR

THO

PED

ICS,

TR

AU

MA

& S

PIN

E

44


2013 TCto

Breil-Wirth A, Jerosch J, Neuhäuser C, Friedrich A (2013): CERASORB® Ortho Foam in Orthopaedics and Traumatology – (Poster P34). Poster presentation, 61st Annual Congress of “Vereinigung Süddeutscher Orthopäden und Unfallchirurgen e.V. (VSOU)“, Baden-Baden, Germany, May 1–4, 2013. Poster in English.

CERASORB® Foam

Comment:

“Initial results of a clinical trial involving CERASORB® Foam for the augmentation and filling of bone defects and substance losses in orthopedic and trauma surgery. CERASORB® Foam proved to be an easy-to-handle and extremely effective ceramic bone substitute without any complications or intolerances.”


2012 TCto

Gruber A, Hübner WD (2012): Knochenersatz mit CERASORB® in der orthopädischen Chirurgie/ Unfallchirurgie und Handchirurgie – Eine 10-Jahresstudie. [Bone substitution with CERASORB® in orthopedic, trauma, and hand surgery – a 10-year longtime study.] Lecture at the „18. Rheuma-Winter-Symposium, ’Innovative Rheumachirurgie und Nachbehandlungskonsequenzen’“, January 21, 2012, RTZ Nürnberg/Germany. Abstract in German.


Comment:

“Prospective long-term study with 102 patients with the following indications: trauma, rheumatism, tumour. There were no allergic reactions or material-caused complications. In nearly all cases the long-term follow-up showed a complete osseointegration and resorption of CERASORB®. Over the course of 10 years the synthetic bone graft CERASORB® has proven to be an alternative to autologous spongiosa as bone void filler.”

OR

THO

PEDIC

S, TRA

UM

A & SPIN

E

45


2009 TCto

Berger S, Kaufmann MM, Siebert CH (2009): Knochenersatzstoffe bei Pfannenwechsel – ein verlässlicher Weg bei älteren Patienten? [Bone replacement materials in hip revision surgery – a reliable way in elder patients?]Lecture No. 235 at the “57. Jahrestagung der Vereinigung Süddeutscher Orthopäden e.V.“, Baden-Baden, Germany, May 1, 2009. Orthopädische Praxis, Special Edition 2009, p. 189. Abstract in German.

CERASORB®

Comment:

“Also in elder patients synthetic bone void fillers can be used in hip revision surgery isolated or in combination with allogenic bone successfully.”

2009 TCto

Rupprecht M, Münch C, Barvencik F, Busse B, Rueger JM, Amling M (2009): β-TricalciumphosphatinderStabilisierungvonTibia-kopffrakturen – Klinische Langzeitergebnisse bei 52 Patienten sowie histologische und rasterelektronen-mikroskopische Subgruppenanalyse. [Stabilisationoftibiaheadfractureswithβ-TCP–Clinicallongterm results in 52 patients as well as histologically and electron microscopically subgroup evaluation.] Presentation, Deutscher Kongress für Orthopädie und Unfall-chirurgie, Berlin, 23.10.2009. Abstract presentation in German.

CERASORB®

Comment:

“Metaphyseal defects of the tibia head can be stabilized sufficiently with β-TCP, where β-TCP is osseointegrated dependent on the particle-size without negative impact on bone regeneration.”


2007 TCto

Maus U, Andereya S, Gravius S, Ohnsorge JAK, Siebert CH, Kaufmann MM, Niedhart C (2007): Klinische Erfahrungen mit dem resorbierbaren Knochenersatzstoff CERASORB®. [Clinical experience with the Resorbable Bone Substitute CERASORB®.] Orthopädische Praxis 2007, 43 (5): 258–261. Article in German.

CERASORB® granules, block forms

Comment:

“In 30 patients with different orthopaedic indications, CERASORB® Granules and Block Forms were used as bone regeneration material. The results of the study show, that CERASORB® is a alternative to the known clinically used bone substitutes because of its biocompatibility and resorption.”

OR

THO

PED

ICS,

TR

AU

MA

& S

PIN

E

46


2006 TCto

Maus U, Andereya S, Ohnsorge J, Siebert CH, Niedhart C (2006): Klinische Testung des resorbierbaren Knochenersatzstoffes CERASORB®.[Clinical Testing of the Resorbable Bone Substitute CERASORB®.] Lecture Nr. 124, 54th Annual Congress, “Vereinigung Süddeutscher Orthopäden”, Baden-Baden 2006, Germany. Abstract in German.

CERASORB®, PRP

Comment:

“This synthetic bone regeneration material is an alternative to autologous spongiosa in the filling of bony defects. After complete resorption, this material leads to a “restitutio-ad-integrum”. The advantage is the low rate of complications compared to autologous spongiosa.”

2006 TCto

Muench C, Schilling AF, Amling M, Rueger JM (2006): Anwendung einer neuen, phasenreinen Beta-Trikalziumphosphatkeramik(β-TCP)zurDefektfüllungnachTibiakopffrakturen. [Application of a new pure beta-tricalcium phosphate ceramic (β-TCP)asvoidfillerintibiaheadfractures.]Lecture on “Deutscher Kongress für Orthopädie und Unfallchirurgie”, Berlin. October 5, 2006. Meeting abstract in German.

CERASORB® granules, block forms

Comment:

“Porous β-TCP as block forms or granules is a suitable bone replacement material for augmentation of metaphysial defects after tibia head fractures.”


2002 TCto

Gruber AA (2002): KnochenaufbaumitBeta-Trikalzium-Phosphat(β-TCP),Erfahrungaus50Anwendungenvonβ-TCPunterbesondererBerücksichtigung der Knochentumoren. [FormationofbonewithBeta-tricalcium-phosphate(β-TCP),experiencefrom50treatmentswithβ-TCPunderspecialregardof bone tumours.] Z Orthop 2002, Abstract M056, Written in German.

CERASORB®

Comment:

“β-TCP CERASORB® was used in 50 patients with bone tumors in fracture reconstruction and in inflammatory rheumatic joint deseases. β-TCP showed a complete resorption and growth of new bone with biomechanic results in terms of real remodelling.”

OR

THO

PEDIC

S, TRA

UM

A & SPIN

E

47


2002 TCto

Redeker J, Meyer-Marcotty M, Entezami A, Fluegel M (2002): Erste Ergebnisse des Einsatzes von CERASORB® zur Auffüllung von Knochendefekten an der Hand. [Initial Results of Using CERASORB® to Fill Bone Defects in the Hand.] Poster presentation, 43rd DAH Symposium, Vienna 2002. Poster in German.

CERASORB®

Comment:

“If the goal of treating of a bone defect is a rapid, unlimited and cost-effective restoration of the hand’s functions, CERASORB® seems to be superior to cancellous bone.”


2001 TCs

Schönmayr R, Schmieder K, Goetz Ch, Weinzierl FX, Eysel P (2001):Anterior Cervical Interbody Fusion with new Titanium-Cages (WING®).Poster presentation at the 12th Worldcongress of Neurosurgery, Sydney 2001.

CERASORB®, (PRP)

Comment:

“In combination with CERASORB® no autologous bone had to be harvested, donor site morbidity could be avoided.”

2001 TCs

Schönmayr R, Ant MR, Melzer M (2001): Anterior Cervical Interbody Fusion with PEEK-Plate-Cages (Scient’x®).Poster presentation at the 12th Worldcongress of Neurosurgery, Sydney 2001.

CERASORB®, (PRP)

Comment:

“After a follow-up of 6 or 12 months respectively, radiologically there was a 100% fusion rate. The CERASORB®-granules were completely resorbed.”

OR

THO

PED

ICS,

TR

AU

MA

& S

PIN

E

48


1999 TCto

Gruber AA (1999): Erfahrungen mit CERASORB® in der Praxis des niedergelassenen Chirurgen.[Experience with CERASORB® in the practice of an independent surgeon.]Der niedergelassene Chirurg 1999, 3 (6): 37–40. Article in German.

CERASORB®

Comment:

“The material is broken down fully and replaced with bone, e.g. when filling bone defects caused by tumors, when performing bone substitution for remodelling and fracture cases or to bridge or fill-in defects to achieve bone union.”

1999 TCto

Gruber AA (1999): Practical Applications of a Bone Substitute – Beta-tricalcium Phosphate in Hand Surgery.TraumaLinc 1999, 2: 50–58.

CERASORB®

Comment:

“The use of beta-tricalcium phosphate removes the need for additional surgery to obtain spongy bone, thus significantly reducing operation time. CERASORB® is thus a highly suitable material for bone regeneration in the field of hand surgery and traumatology.”

OR

THO

PEDIC

S, TRA

UM

A & SPIN

E

49

SCIEN

TIFIC FU

ND

AM

ENTA

LS

SF49


2020 PMTCtos

Peters F, Bahrini K, Placht AM, Gelinsky M (2020):Beladung und kontrollierte Freisetzung von Antibiotika aus Bio-materialien für die Knochenregeneration. [Loading and controlled release of antibiotics from biomaterials for bone regeneration.]OUP 2020; 9 (1). Article in German.

CERASORB® M,CERASORB®

Foam

Comment:

“The results of in vitro loading tests and release kinetics of various antibiotics (vancomycin, gentamicin, meropenem) from CERASORB® granules and CERASORB® Foam are presented. An important aspect is the minimum inhibitory concentration (MHK or minimum inhibitory concentration, MIC), i. e. the minimum concentration of the active substance, which must be on site in order to achieve antibacterial activity. Commercially available antibiotic preparations can be mixed with the biomimetic bone regeneration materials of the CERASORB® product range. It turns out that both the loading capacity of the materials as well as the release kinetics, the concentration of active ingredients over time, in the environment of the biomaterials are always above the MHK and below the toxic limit.”

2020 Ptosd

Al Maawi S, Rutkowski JL, Sader R, Kirkpatrick CJ, Ghanaati S (2020):Thebiomaterial-inducedcellularreactionallowsanovelclassifi-cation system regardless of the biomaterials origin.J Oral Implantol, 2020 Jun 1;46(3):190-207. doi: 10.1563/ aaid-joi-D-19-00201

CERASORB®

CLASSIC,CERASORB® M

Comment:

“The article proposes a new classification system of polymeric biomaterials and bone substitute materials according to the in vivo induced cellular reaction and the clinical consequence of the biomaterial-specific cellular reaction for the regeneration process. The classification is derived from a retrospective animal study which tested 13 polymeric biomaterials and 19 bone substitute materials (BSMs) of various compositions and origins. The cellular reaction was semi-quantitatively analyzed at days 3, 15, and 30 after implantation according to a standardized score for the induction of multinucleated giant cells (MNGCs) and vascularization rate.• Polymeric Biomaterials: The induction of MNGCs and their

increase over 30 days resulted in disintegration of the biomaterial. By contrast, the absence of MNGCs resulted in an integration of the biomaterial within the host tissue. – Tefguide® induced MNGCs with increasing tendency

from days 3 to 30 and was grouped in class III of polymeric biomaterials undergoing no tissue integration.

• BSMs: For the BSMs the observed cellular reaction did not depend on the material origin but on the physicochemical characteristics of the material (i.e., porosity, surface characteristics, processing technique, polarity). – The CERASORB® variants tested induced either MNGCs

with constant number over 30 days and constant vascularization (Class II) or an increasing number of MNGCs over 30 days, rapid degradation and increasing tendency of vascularization.”

SCIE

NTI

FIC

FU

ND

AM

ENTA

LS

SF50


2020 Pd

Dai J, Umrath F, Reiner S, Alexander D (2020):Jaw periosteal cells seeded in beta-tricalcium phosphate inhibit dendritic cell maturation.Biomolecules, 2020 Jun 10;10(6):887. doi: 10.3390/biom10060887.

CERASORB®

Comment:

“Dendritic cells (DCs) are the most potent antigen-presenting cells (APCs) widely distributed in the human body. They play a crucial role in initiating and regulating immune reactions by promoting antigen-specific T cell activation. The studyinvestigated the effect of human jaw periosteal cells (JPCs) seeded in beta-tricalcium phosphate (β-TCP) scaffolds on monocyte-derived dentritic cell (DC) differentiation and maturation. It was shown that JPCs seeded on β-TCP scaffolds inhibit pro-inflammatory cytokine expression and induce anti-inflammatory cytokineexpression. The findings lead to the speculation that JPCs represent a promisingstem cell source for bone tissue regeneration particularly because they are simple to harvest.”

2020 Ptosd

Nohara K, Itoh S, Akizuki T, Nakamura M, Fukuba S, Matsuura T, Okada M, Izumi Y, Iwata T, Yamashita K (2020):Enhanced new bone formation in canine maxilla by a graft of electricallypolarizedβ-tricalciumphosphate.J Biomed Mater Res B Appl Biomater. 2020;108B:2820–2826. https://doi.org/10.1002/jbm.b. 34612.

CERASORB® M

Comment:

“Authors developed a technique to electrically polarize ceramics. Preclinical animal study using electrically polarized β-TCP granules (CERASORB® M) to confirm that electrical charge promotes the initiation of new bone formation.”

OR

THO

PEDIC

S, TRA

UM

A & SPIN

E

51

SCIEN

TIFIC FU

ND

AM

ENTA

LS

SF51


2019 Ptosd

Knabe C, Adel-Khattab D, Hübner WD, Peters F, Knauf T, Peles-ka B, Barnewitz D, Genzel A, Kusserow R, Sterzik F, Stiller M, Müller-Mai C (2019) Effect of silicon-doped calcium phosphate bone grafting materials on bone regeneration and osteogenic marker expression after im-plantation in the ovine scapula J Biomed Mater Res B Appl Biomater. 2019 Apr;107(3):594-614. doi: 10.1002/jbm.b.34153. Epub 2018 May 16.

CERASORB® M,Ceracell®,Osseolive®

Comment:

“Whether silicate doping of TCP and a calcium alkali orthophosphate (CAOP) may enhance osteogenesis when compared to native TCP was investigated in 36 adult female merino sheep using the products CERASORB®, Ceracell®, and Osseolive®. Implantation of all 3 grafting materials facilitated excellent bony regeneration of critical-size defects in the sheep scapula at 3 and 6 months with further bone remodelling at 12 and 18 months, while bone formation in empty control defects was only minor. Grafting materials differed mainly in their resorbability. Healing was uneventful with all animals. None of the test animals showed any clinical signs of inflammation. Si-CAOP induced the most expeditious bone regeneration of critical size defects in the sheep scapula. As a result, all three grafting materials can be regarded as excellent bone grafting materials which are well suited for different clinical applications, in which varying degrees of resorbability are required.”

2019 PMDCd

Lee D, Choi EJ et al. (2019):Injectablebiodegradablegelatin-methacrylate/β-tricalcium phosphate composite for the repair of bone defects.Chemical Engineering Journal 365 (2019) 30-39.

CERASORB® M

Comment:

“The chemical and physical properties of a prepared gelatin/methacrylic anhydride composite (GelMA) and a composite with GelMA hydrogel incorporating β-TCP (CERASORB® M) (GelMA-B) GelMA-B are reported. The gelatin-methacrylate (GelMA) hydrogel was applied into the β-TCP to produce a GelMA/β-TCP composite (GelMAB). This reinforced the mechanical strength and regulated the absorption period of β-TCP. To characterize the physical properties of the formed composite, GelMA-B was tested using a mechanical tester and a rheometer; biocompatibility, osteogenic differentiation was assessed and bone regeneration in an animal study tested. GelMA-B showed higher mechanical strength than β-TCP and GelMA alone. GelMA-B maintained its volume and shape during regrowth.

SCIE

NTI

FIC

FU

ND

AM

ENTA

LS

SF52


2019 Po

Roth KE, Maier GS, Schmidtmann I, Eigner U, Hübner WD, Pe-ters F, Drees P, Maus U (2019): Release of antibiotics out of a moldablecollagen-β-tricalciumphosphate-compositecompared to two calcium phosphate granules. Materials (Basel). 2019 Dec 5;12(24). pii: E4056. doi: 10.3390/ma12244056.

CERASORB® Foam,CERASORB® M,Osbone®

Comment:

“The study investigated the loading capacity and the release rate of Vancomycin and Gentamicin on TCP granules (CERASORB® M) and HA granules (Osbone®) compared to composite materials from TCP mixed with porcine collagen (CERASORB® Flexible Foam Strip) after mixing under simulated clinical conditions without additional loading and drying steps. The loading capacity of the biomaterials was measured and compared according to the Minimum Inhibition Concentration (MIC) and the Minimum Biofilm Eradication Concentration (MBEC) of a bacterial biofilm after 24 h aging. Generally, the antibiotic release is more pronounced during the first couple of days than later, yet for TCP granules and HA granules much faster (within the first three days) than for the composite material TCP and porcine collagen which showed drug release in the frame of the specification during the first nine days. This material showed also a much higher loading capacity.”

OR

THO

PEDIC

S, TRA

UM

A & SPIN

E

53

SCIEN

TIFIC FU

ND

AM

ENTA

LS

SF53


2018 Ptosd

AnghelescuVM,NeculaeI,DincăO,VlădanC,SocoliucC, Cioplea M, Nichita L, Popp C, Zurac S, Bucur A (2018): Inflammatory-drivenangiogenesisinboneaugmentationwith bovine hydroxyapatite, b-tricalcium phosphate, and bioglasses: A comparative study. J Immunol Res. 2018 Sep 12;2018:9349207, 8 pages. doi: 10.1155/2018/9349207. eCollection 2018.

CERASORB® M

Comment:

“The study analyses the ability to integrate bone substitutes in an animal model. 3 different bone grafts were tested: beta-tricalcium phosphate (CERASORB®), bovine hydroxyapatite (Bio-Oss®, Geistlich Biomaterials), and bioactive glasses (PerioGlas®, Novabone; 45% SiO2 (silica dioxide), 24.5% CaO (calcium oxide), 24.5% NaO2 (sodium oxide), and 6% P2O5 (phosphorus pentoxide). The ability to integrate the bone grafts was tested by the extent of angiogenesis and the immunohistochemical expression of the platelet endothelial cell adhesion molecules, the vascular endothelial growth factor, collagen IV, laminin, and osteonectin, in the vicinity of bone grafts. The appearance of bone lamellae was tested as well. Standardized monocortical defects in the tibia of 20 New Zealand rabbits were set. 6 defects were filled with each material. After a period of 6 months, bone fragments were harvested for histopathologic examination. The amount of bone that is formed around beta-tricalcium phosphate and bovine hydroxyapatite is clearly superior to the bioactive glasses. They have significant increased angiogenesis (and subsequent improved osteogenesis) comparing with PerioGlas®. Both the lumen diameter and the number of vessels were slightly increased in favor of β-tricalcium phosphate.”

SCIE

NTI

FIC

FU

ND

AM

ENTA

LS

SF54


2018 Ptosd

Faigle G, Bernstein A, Suedkamp NP, Mayr HO, Peters F, Hueb-ner WD, Seidenstuecker M (2018): Release behavior of VAN from four types of CaP-ceramic gran-ules using various loading methods at two different degrees of acidity. J Mater Sci: Mater Med (2018) 29: 12. https://doi.org/10.1007/s10856-017-6006-4. (14 pages).

CERASORB® Foam,CERASORB® M,Ceracell®,Osseolive®

Comment:

“The release behavior of vancomycin (VAN) from four types of ceramic granules, developed by curasan, was investigated in this in-vitro study:• Ceracell®, a phase pure β-tricalciumphosphate (β-TCP)

with silicate;• Osseolive®, a calcium-potassium-sodium-phosphate

glass ceramic with silicate;• Osbone®, a pure ceramic of hydroxyapatite (HA);• CERASORB® Foam, a highly porous composite of

porcine collagen (collagencomposite) and phase pure β-TCP granules of variable size and density.

The influence of VAN concentration and pH on release behavior was analyzed over 14 days after loading the substrates with VAN using different loading and drying techniques. At pH 7.4 and a concentration of 5 mg/ml the cumulative release of the antibiotic from the granules was higher compared to the foam. However, when a concentration of VAN 50 mg/ml was applied, the cumulative vancomycin release was higher with the foam compared to the granules.”

2018 Pd

Ishikawa K, Miyamoto Y, Tsuchiya A, Hayashi K, Tsuru K, Ohe G (2018): Physical and histological comparison of hydroxyapatite, carbonateapatite,andβ-tricalciumphosphatebonesubstitutes.Materials (Basel). 2018 Oct 16;11(10). pii: E1993. doi: 10.3390/ma11101993.

CERASORB®

Comment:

“Three commercially available artificial bone substitutes with different compositions, hydroxyapatite (HAp; Neobone®), carbonate apatite (CO3Ap; Cytrans®), and – tricalcium phosphate (β-TCP; CERASORB®), were compared with respect to their physical properties and tissue response to bone in hybrid dogs. Three months following the extraction of premolars and molars, bone defects of 3.6 mm in diameter and 8 mm in depth were made in the alveolar bone and filled with graft. Histological evaluation was done at 4 and 12 weeks. CERASORB® had lowest bone formation at 4 weeks, but significant increase at 12 weeks.”

OR

THO

PEDIC

S, TRA

UM

A & SPIN

E

55

SCIEN

TIFIC FU

ND

AM

ENTA

LS

SF55


2017 Pd

da Silva de Oliveira JC, Luvizuto ER, Sonoda CK, Okamoto R, Garcia-Jùnior IR (2017): Immunohistochemistry evaluation of BMP-2withβ-tricalciumphosphatematrix,polylacticandpolygly-colic acid gel, and calcium phosphate cement in rats. Oral Maxil-lofac Surg. 2017 Jun;21(2):247-258. doi: 10.1007/s10006-017-0624-3. Epub 2017 Apr 8.

CERASORB® M

Comment:

“A total of 144 calvaria defects (5-mm diameter) were randomly divided into eight treatment groups, with a total of 18 defects per treatment group. The treatment groups were as follows: (1) 500–1000 μm β-tricalcium phosphate (β-TCP) (CERASORB® M, Curasan AG, Germany), (2) β-TCP plus 5 μg BMP-2 (R&D Systems, Inc., Minneapolis, MN, USA), (3) polylactic and polyglycolic acid gel (PLA/PGA) (Fisiograft®, Ghimas SPA, Italy), (4) PLA/PGA plus BMP-2, (5) calcium phosphate cement (CPC) (Norian® CRS®, Craniofacial Repair System®, Germany), (6) CPC plus BMP-2, (7) empty control (untreated), and (8) the autograft control.” “β-TCP alone had the highest amount of new bone and the largest amount of mineralized tissue, although there has been no statistical difference with supplementation with BMP-2. One of the most influential factors in the resorption process of β-TCP has been found to be the macroporosity and microporosity that promote the ingrowth of blood vessels and enable osteocyte dendrites to infiltrate the micropores.”

2017 Pd

de Assis Gonzaga F, de Miranda TT, Magalhães LMD, Dutra WO, Gollob KJ, Souza PEA, Horta MCR (2017): Effects of Bio-Oss® and CERASORB® dental M on the expression of bone-remodel-ing mediators in human monocytes. J Biomed Mater Res B Appl Biomater. 2017 Oct;105(7):2066-2073. doi: 10.1002/jbm.b.33747. Epub Jul 12.

CERASORB® Dental M,CERASORB® M,CERASORB®

Comment:

“The study evaluates the effect of the bone-grafting materials Bio-Oss® and CERASORB® M on the expression of cytokines associated with bone remodeling in vitro. The expression of cytokines by human monocytes was analyzed with and without stimulation by a bacterium which can cause periimplantitis.” “The data suggest that Bio-Oss® and CERASORB® M neither stimulate cytokine production in human monocytes nor interfere with mechanisms of cell communication mediated by cytokines stimulated by P. gingivalis.”

SCIE

NTI

FIC

FU

ND

AM

ENTA

LS

SF56


2017 Ptod

Hosseinpour S, Ghazizadeh Ahsaie M, Rezai Rad M, Baghani MT, Motamedian SR, Khojasteh A (2017): Application of selected scaffolds for bone tissue engineering: a systematic review. Oral Maxillofac Surg. 2017 Jun;21(2):109-129. doi: 10.1007/s10006-017-0608-3. Epub 2017 Feb 13.

CERASORB®,PRP

Comment:

“Review on how combinations of various mesenchymal stem cells, scaffolds, and growth factors enhance bone regeneration; mainly in animal studies. In this review, bone marrow mesenchymal cells (BMMSCs) are the most studied MSCs, β-TCP is the most frequently used scaffold, and platelet rich plasma (PRP) is the most commonly used growth factor.”

2017 Pd

Motamedian SR, Tabatabaei FS, Akhlaghi F, Torshabi M, Gholamin P, Khojasteh A (2017): Response of Dental Pulp Stem Cells to Synthetic, Allograft, and Xenograft Bone Scaffolds. Int J Periodontics Restorative Dent. 2017 Jan/Feb;37(1):49-59. doi: 10.11607/prd.2121.

CERASORB®,CERASORB® M,granules, block forms

Comment:

“The effect of β-tricalcium phosphate (β-TCP/CERASORB® M), freezed-dried bone allograft (FDBA) and deproteinized bovine bone mineral (DBBM) on cell proliferation, cell differentiation and attachment was analyzed. Dental pulp stem cells (DPSC) were used as they differentiate into osteoblast and produce mineralized matrix. β-TCP had the highest potential for DPSC attachment and proliferation, while FDBA induced osteoblastic differentiation in DPSCs.”

2017 Pdo

Tabatabaei FS, Samadi R, Tatari S (2017): Surface characteris-tics of three commercially available grafts and adhesion of stem cells to these grafts. Biomed Mater Eng. 2017;28(6):621-631. doi: 10.3233/BME-171700.

CERASORB® M

Comment:

“In vitro study was conducted to compare the surface characteristics of betatricalcium phosphate (β-TCP) alloplast, a mixture of demineralized bone matrix and mineralized bone allograft (DBM&MBA) and natural bovine bone mineral (NBBM) xenograft and the adhesion of dental pulp stem cells (DPSCs) to the grafts. Patterns of β-TCP and NBBM samples in XRD and FTIR spectroscopy showed high resemblance and elongated cells were seen after 24 h on the β-TCP and DBM&MBA surfaces, but not on the NBBM surface.”

OR

THO

PEDIC

S, TRA

UM

A & SPIN

E

57

SCIEN

TIFIC FU

ND

AM

ENTA

LS

SF57


2016 Pd

Barbeck M, Hoffmann C, Sader R, Peters F, Hübner WD, Kirkpat-rick CJ, Ghanaati S (2016): Injectable bone substitute based on β-TCPcombinedwithahyaluronan-containinghydrogelcontrib-utes to regeneration of a critical bone size defect towards restitu-tio ad integrum. J Oral Implantol, 2016, 42 (2): 127-137. Doi: 10.1563/aaid-joi-D-14-00203. Epub 2015 Aug 24.

CERASORB® Paste

Comment:

“The results of the present study demonstrate that the injectable bone substitute (CERASORB® Paste) contributes to sufficient bone regeneration by serving as a scaffold-like structure, combined with its degradation within six months.”

2016 Ptod

Bizenjima T, Takeuchi T, Seshima F, Saito A (2016): Effect of poly (lactide-co-glycolide) (PLGA)-coated beta-tricalcium phosphate on the healing of rat calvarial bone defects: a comparative study with pure-phase beta-tricalcium phosphate. Clin Oral Implants Res. 2016 Nov;27(11):1360-1367. doi: 10.1111/clr.12744. Epub 2016 Jan 8.

CERASORB®

Comment:

“The study compares the effect of poly (lactide-co-glycolide) (PLGA)-coated β-tricalcium phosphate (TCP) as a scaffold on bone regeneration in 20 rat calvaria with pure-phase β-TCP. Defects of each rat were filled with pure-phase β-TCP or PLGA/β-TCP, or left as unfilled control. The healing was evaluated by microcomputed tomography, histological, and immunohistochemical analyses. Defect closure and new bone area at 4 and 6 weeks was larger in the β-TCP samples than in the PLGA-coated β-TCP.”

2016 Ptod

Luvizuto ER, Tangl S, Dobsak T, Reich K, Gruber R, Sonoda CK, Okamoto R (2016): Effect of recombinant PDGF-BB on bone for-mationinthepresenceofβ-tricalciumphosphateandbovinebone mineral matrix: a pilot study in rat calvarial defects. BMC Oral Health. 2016 May 4;16(1):52. doi: 10.1186/s12903-016-0210-3.


Comment:

“Evaluation on the effect of the recombinant platelet-derived growth factor-BB (PDGF-BB) on bone formation in the presence of β-tricalcium phosphate and bovine bone mineral matrix in a rat calvaria defect model. 5 mm rat calvarial defects treated with β-tricalcium phosphate (TCP/CERASORB® M) or demineralized bovine bone mineral (DBBM/Bio-Oss®) with and without 0.3 mg/ml recombinant PDGF-BB were examined. Newly formed bone area was highest with TCP and TCP plus PDGF-BB.”

SCIE

NTI

FIC

FU

ND

AM

ENTA

LS

SF58


2015 Pd

Barbeck M, Hoffmann C, Sader R, Peters F, Hübner WD, Kirkpatrick CJ, Ghanaati S (2015):Injectablebonesubstitutebasedonβ-TCPcombinedwithahyaluronan-containing hydrogel contributes to regeneration of a critical bone size defect. J Oral Implantol. 2015 Aug 24. [Epub ahead of print]. Abstract.

CERASORB® Paste

Comment:

“The results of the present study demonstrate that the injectable bone substitute (CERASORB® Paste) contributes to sufficient bone regeneration by serving as a scaffold-like structure, combined with its degradation within six months.”

2015 Ptosd

Knabe C, Lopez-Heredia M, Barnewitz D, Genzel A, Peters F, Kuhr A, Stang B, Hübner WD (2015): Effect of tricalcium phosphate-based paste- and foam-like bone grafting materials on bone regeneration and osteogenic marker expression in vivo. Lecture, 41th Annual Meeting of the Society for Biomaterials in Charlotte, NC, USA, 16.04.2015, Abstract.

CERASORB® Foam, CERASORB® Paste, CERASORB® M

Comment:

“In a sheep study critical size defects in the scapula were filled with three different β-TCP-based bone regeneration materials [CERASORB® M Granules, CERASORB® Foam, CERASORB® Paste] and studied over 18 months. CERASORB® Foam as well as CERASORB® Paste showed extraordinary bone regeneration with a little higher osteogenetic potential compared to CERASORB® granules.”

2015 Ptosd

Lopez-Heredia MA, Barnewitz D, Genzel A, Stiller M, Peters F, Huebner WD, Stang B, Kuhr A, Knabe C (2015): In vivo osteogenesis assessment of a tricalcium phosphate paste and a tricalcium phosphate foam bone grafting material. Bioceramics 26: Key Engineering Materials Vol. 631 (2015):426–429.doi:10.4028/www.scientific.net/KEM.631.426.

CERASORB® M,CERASORB® Foam,CERASORB® Paste

Comment:

“Critical-size defects in the sheep scapula were filled with three different β-TCP based bone void fillers [CERASORB® M Granules, CERASORB® Foam, and CERASORB® Paste] and studied for 18 months. Both, the β-TCP foam and paste materials displayed advantageous surgical handling properties and facilitated excellent bone regeneration and repair of the critical-size defects, similar to that of the clinically established TCP granules while exhibiting greater biodegradability.”

OR

THO

PEDIC

S, TRA

UM

A & SPIN

E

59

SCIEN

TIFIC FU

ND

AM

ENTA

LS

SF59


2014 Ptosd

Barbeck M, Lorenz J, Landes C, Sader RA, Kirkpatrick CJ, Ghanaati S (2014): Injectablebonesubstitutebasedonβ-TCPgranules.Resultsfrom an in-vivo analysis in Wistar rats. implants 2014; 15 (2): 6–12.

CERASORB® Paste

Comment:

“In a subcutaneous implantation model in Wistar rats over a time period of 60 days the material underwent continuous degradation from the periphery towards the core. The combination increased the vascularisation of the implantation bed, which is essential for successful tissue generation.”

2014 Ptosd

Knabe C, Lopez-Heredia M, Barnewitz D, Genzel A, Peters F, Kusserow R, Hübner WD (2014): Effect of silicon-doped calcium phosphate bone substitute on bone formation and osteoblastic phenotype expression in vivo. Bioceramics 25: Supplement, Key Engineering Materials Vol. 614 (2014):31–34.doi:10.4028/www.scientific.net/KEM.614.31.

CERASORB® M, Ceracell®, Osseolive®

Comment:

“Study evaluates the effect of two novel particulate silicon-doped calcium phosphate graft materials as compared to the currently clinically used material β-TCP on osteogenesis and bone formation after implantation in critical-size defects the sheep scapula. These materials were developed in order to create biodegradable bone substitute materials that degrade rapidly, but still stimulate osteogenesis at the same time, thereby resulting in bone repair and regeneration with fully functional bone tissue. All bone substitute materials studied facilitated excellent bony regeneration of critical-size defects in the sheep scapula. (Osseolive®, Ceracell®, CERASORB® M).”

2014 Ptod

Krause M, Oheim R, Catala-Lehnen P, Pestka JM, Hoffmann C, Huebner W, Peters F, Barvencik F, Amling M (2014): Metaphysealboneformationinducedbyanewinjectableβ-TCP-based bone substitute: A controlled study in rabbits. J Biomater Appl. 2014 Feb; 28(6):859–68. doi: 10.1177/0885328213484816. Epub 2013 May 13.

CERASORB® Paste

Comment:

“In a unilateral tibia defect model the peri-implant and bone tissue response to the new pasty bone substitute was tested in New Zealand white rabbits up for 24 weeks compared to empty controls. Already after one week the experimental group presented significantly higher new bone fraction. There were no signs of inflammation at all times.”

SCIE

NTI

FIC

FU

ND

AM

ENTA

LS

SF60


2014 Ptod

Zheng H, Bai Y, Shih M-S, Hoffmann C, Peters F, Waldner C, Hübner W-D. (2014): Effectofaβ-TCPcollagencompositebonesubstituteonhealingof drilled bone voids in the distal femoral condyle of rabbits. J Biomed Mater Res Part B 2014; 102B: 376–383.

CERASORB® Foam

Comment:

“The performance and biocompatibility of a composite of β-TCP and collagen as a bone void filler was tested in a rabbit distal femoral condyle model over 6 months. Compared to control [empty defects] all evaluations revealed significantly better bone healing. No signs of inflammation were observed.”


2013 Ptosd

Bernhardt A, Lode A, Peters F, Gelinsky M (2013): Comparative evaluation of different calcium phosphate-based bone graft granules – an in vitro study with osteoblast-like cells. Clin Oral Implants Res. 2013 Apr; 24 (4): 441–449. doi: 10.1111/j.1600-0501.2011.02350.x. Epub 2011 Oct 24.


Comment:

“In the present study good cell adhesion and proliferation of SaOS-2 cells on CERASORB® M could be demonstrated.”

2013 Pd

Ghanaati S, Barbeck M, Hoffmann C, Peters F, Hübner W, Sader R, Kirkpatrick C (2013): Knochenregeneration mit einem injizierbaren pastösen KnochenersatzmaterialaufderBasisvonβ-TCPundNatriumhyaluronat im distalen Kaninchenfemur. [Bone regeneration with an injectable pasty bone substitute on thebasisofβ-TCPandnatriumhyaluronateinthedistalrabbitfemur.] Lecture, 61st Annual Meeting of “Vereinigung Süddeutscher Orthopäden e.V. (VSOU)“, Baden-Baden, Germany, May 1–4, 2013. Abstract in German.

CERASORB® Paste

Comment:

“Critical size defects in the distal femur condyles of rabbits were filled with CERASORB® Paste. After 6 months the material was nearly completely degraded and a homogeneous filling by means of directed osteoconduction could be shown.”

OR

THO

PEDIC

S, TRA

UM

A & SPIN

E

61

SCIEN

TIFIC FU

ND

AM

ENTA

LS

SF61


2013 Ptod

Knabe C, Barnewitz D, Genzel A, Peters F, Lopez-Heredia M, Kusserow R, Hübner WD (2013): Effect of silicon-doped calcium phosphate bone grafting materials on bone formation and osteoblastic phenotype expression in vivo. ORS [Orthopaedic Research Society] 2013 Annual Meeting; January 26–29, 2013; San Antonio, Texas, USA, Poster Nr. 0777.


Comment:

“By 3 and 6 months all bone grafting materials CERASORB® M, Ceracell®, and Osseolive® facilitated excellent bone regeneration of critical-size defects in the sheep scapula with further bone remodelling at 12 and 18 months.”

2013 Ptod

Knabe C, Lopez-Heredia M, Barnewitz D, Genzel A, Peters F, Kusserow R, Hübner WD (2013):Effect of silicon-doped calcium phosphate bone substitute on bone formation and osteoblastic phenotype expression in vivo. 25th Symposium and Annual Meeting of the International Society for Ceramics in Medicine – BIOCERAMICS 25, Bucharest, Romania, November 07–10th 2013. Lecture OS 6, Nov., 08, 2013.


Comment:

“Critical-size defects in the sheep scapula were filled with the three different particulate bone grafting materials [CERASORB® M, Ceracell®, and Osseolive®]. By 3 and 6 months all facilitated excellent bone regeneration with further bone remodelling at 12 and 18 months and without any signs of inflammation.”

2013 Ptod

Maier GS, Roth KE, Andereya S, Birnbaum K, Niedhart C, Lühmann M, Ohnsorge J, Maus U (2013): In vitro elution characteristics of gentamicin and vancomycin from synthetic bone graft substitutes. Open Orthop J. 2013 Nov 3; 7: 624–629. doi: 10.2174/1874325001307010624. eCollection 2013.

CERASORB®, CERASORB® M, antibiotic

Comment:

“CERASORB® und CERASORB® M granulates were loaded with gentamicin and vancomycin. Antibiotic elution and concentration profiles were measured, showing initially a high release of the loaded antibiotics, overall lasting for CERASORB® M for about four, for CERASORB® granulates for about six days.”

SCIE

NTI

FIC

FU

ND

AM

ENTA

LS

SF62


2013 Pd

Polo CI, Lima JL, De Lucca L, Piacezzi CB, Naclério-Homem Mda G, Arana-Chavez VE, Sendyk WR (2013): Effect of recombinant human bone morphogenetic protein 2 associated with a variety of bone substitutes on vertical guided bone regeneration in rabbit calvarium. J Periodontol. 2013 Mar;84(3):360-70. doi: 10.1902/jop.2012.110674. Epub 2012 Apr 23.

CERASORB®

Comment:

“Evaluation of the effect of recombinant human bone morphogenetic protein 2 (rhBMP-2) associated with bone substitute materials beta-tricalciumphosphate (β-TCP/CERASORB®), biphasic calcium phosphate (BCP), and bovine bone mineral on vertical guided bone regeneration (GBR) in rabbit calvarium. rhBMP-2/ACS significantly increases bone formation in a rabbit calvarium GBR model when combined with any of the three bone substitute materials used in this study, namely b-TCP, BCP, and BBM, which acted as additional carriers.”

2013 Pd

Viale-Bouroncle S, Buergers R, Morsczeck C, Gosau M (2013): β-Tricalciumphosphateinducesapoptosisondentalfolliclecells.Calcif Tissue Int. 2013 May;92(5):412-7. doi: 10.1007/s00223-012-9694-2. Epub 2013 Jan 20.

CERASORB®

Comment:

“Investigated the attachment, survival, and proliferation of dental follicle cells (DFCs) on TCP in more detail. The TCP scaffold released fine soluble particles enriched in TCP eluates that induced cell death and showed typical characteristics of programmed cell death (apoptosis) in DFCs. During cultivation on the TCP scaffold, DFCs showed a highly upregulated expression of antiapoptotic genes but a downregulated expression of proapoptotic markers. In conclusion, TCP supports osteogenic differentiation in DFCs but also induces programmed cell death.”

OR

THO

PEDIC

S, TRA

UM

A & SPIN

E

63

SCIEN

TIFIC FU

ND

AM

ENTA

LS

SF63


2011 Ptod

Batista MA, Leivas TP, Rodrigues CJ, Arenas GC, Belitardo DR, Guarniero R (2011): Comparison between the effects of platelet-rich plasma and bone marrow concentrate on defect consolidation in the rabbit tibia. Clinics (Sao Paolo) 2011; 66 (10): 1787–1792.

CERASORB®, PRP

Comment:

“20 rabbits with bone defects in the proximal tibia were randomly treated with β-tricalciumphosphate and PRP or BMC. After four weeks all animals showed good bone consolidation. The evaluation revealed a greater amount of consolidation and the formation of greater cortical bone thickness in the PRP group.”

2011 Ptod

Ghanaati S, Barbeck M, Hilbig U, Hoffmann C, Unger RE, Sader RA, Peters F, Kirkpatrick CJ (2011): An injectable bone substitute composed of beta-tricalcium phosphate granules, methylcellulose and hyaluronic acid inhibits connectivetissueinfluxintoitsimplantationbedinvivo. Acta Biomater 2011, 7 (11): 4018–4028.

CERASORB® Paste

Comment:

“In a subcutaneous implantation model in rats the material underwent continuous degradation from the periphery towards the core. The combination increased the vascularisation of the implantation bed, which is essential for successful tissue generation.”

2011 Pto

Luvizuto ER, Tangl S, Zanoni G, Okamoto T, Sonoda CK, Gruber R, Okamoto R (2011): The effect of BMP-2 on the osteoconductive properties of β-tricalciumphosphateinratcalvariadefects.Biomaterials. 2011 May; 32 (15): 3855–3861. Epub 2011 Mar 3.

CERASORB® M

Comment:

“Rat calvaria critical sized defects were treated with CERASORB®, different other bone void fillers and autografts. The authors conclude that the osteoconductive properties of β-TCP CERASORB® are superior to those of autografts and that TCP does not require BMP-2 supplementation.”

SCIE

NTI

FIC

FU

ND

AM

ENTA

LS

SF64


2011 Pd

Viale-Bouroncle S, Bey B, Reichert TE, Schmalz G, Morsczeck C (2011):β-tricalcium-phosphatestimulatesthedifferentiationofdental follicle cells. J Mater Sci Mater Med. 2011 Jul;22(7):1719-24. doi: 10.1007/s10856-011-4345-0. Epub 2011 May 22.

CERASORB®

Comment:

“The study investigated cell attachment (scanning electron microscopy), cell vitality/proliferation (WST-1 assay) and cell differentiation (under in vitro conditions) of human dental follicle cells (DFCs) on synthetic β-tricalcium phosphate (TCP/CERASORB®). DFCs showed considerable cell attachment and proliferation on TCP. Moreover, TCP stimulates osteogenic differentiation in comparison to DFCs with a standard protocol. Here, for example, the osteoblast marker bone sialoprotein (BSP) was highly expressed on TCP, but almost absent in differentiated DFCs without TCP. In conclusion, our study shows that TCP is an excellent scaffold for DFCs for oral tissue regeneration.”


2010 Ptod

Ghanaati S, Barbeck M, Orth C, Willershausen I, Thimm BW, Hoffmann C, Rasic A, Sader RA, Unger RE, Peters F, Kirkpatrick CJ (2010): Influenceofβ-tricalciumphosphategranulesizeandmorphologyon tissue reaction in vivo.Acta Biomater 2010, Dec; 6 (12): 4476–4487. Epub 2010 Jul 23.

CERASORB®, CERASORB® M, CERASORB® Paro/Perio

Comment:

“Five different β-tricalcium phosphate based bone substitute materials induced the formation of TRAP-positive multinucleated giant-cells as a sign of biomaterial stability. These cells directly influenced the vascularisation by secretion of VEGF as well as other chemokines.”

OR

THO

PEDIC

S, TRA

UM

A & SPIN

E

65

SCIEN

TIFIC FU

ND

AM

ENTA

LS

SF65


2009 Ptosd

Bernhardt A, Lode A, Hänel T, Peters F, Gelinsky M (2009): Perfusion culture of osteogenic induced mesenchymal stem cells onmilledβ-tricalciumphosphate(β-TCP)scaffolds.Poster presentation, 3rd CRTD summer conference on regenerative medicine, Dresden, 26.06.2009.

CERASORB®

Comment:

“Ceramic scaffolds from pure β-TCP with large interconnecting channels are suitable for expansion and osteogenic differentiation of hMSC in vitro.”

2009 Ptosd

Bernstein A, Mayr HO, Görz L, Siebert C (2009): Tissue Engineering von osteochondralen Defekten auf der Basis von resorbierbaren Scaffolds.[Tissue engineering of osteochondral defects based on resorbable scaffolds.] Poster presentation, Deutscher Kongress für Orthopädie und Unfallchirurgie, Berlin, 21.10.2009. Poster in German.

CERASORB®

Comment:

“Mesenchymal stem cells from the bone-narrow of sheep were isolated and cultivated in vitro under a standardized procedure. It could be shown, that the mesenchymal the stem-cells as well as the chondrocytes could be cultivated on the scaffolds without any problem. Microporous TCP-implants are suitable for tissue-engineering.”

2009 Pto

Hauschild G, Muschter N, Richter A, Ahrens H, Gosheger G, Fehr M, Bullerdiek J (2009): Cartilage replacement in dogs – A preliminary investigation of colonization of ceramic matrices.Vet Comp Orthop Traumatol. 2009, 22 (3): 216–221.

CERASORB®

Comment:

“In an in-vitro study the ceramic is well accepted by canine chondrocytes, and appears to be fundamentally well-suited as a matrix for bio-cartilage replacement.”

2009 Ptosd

Herten M, Rothamel D, Schwarz E, Friesen K, Koegler G, Becker J (2009): Surface- and nonsurface-dependent in vitro effects of bone substitutes on cell viability.Clin Oral Investig. 2009 Jun; 13 (2): 149–155. Epub 2008 Aug 8.

CERASORB®

Comment:

“In an in-vitro study with 6 different bone substitutes and 3 different cell lines, CERASORB® showed very good cell viability factors with adherent and non-adherent cell cultures.”

SCIE

NTI

FIC

FU

ND

AM

ENTA

LS

SF66


2009 Pd

Knabe C, Berger G, Gildenhaar R, Koch Ch, Axmann I, Jonscher S, Rack A, Ducheyne P, Stiller M (2009): Effect of rapidly resorbable calcium-alkali-orthophosphate bone graftingmaterialsonosteogenesisaftersinusflooraugmentationin sheep. Society For Biomaterials. 2009 Annual Meeting and Exposition. April 22–25, 2009, San Antonio, Texas; Oral Presentation, Abstract.

CERASORB®, Osseolive®

Comment:

“Of the various grafting materials studied, GB9/25 showed the best bone bonding and regenerative behaviour, closely followed by β-TCP.”

2009 Ptosd

Lange T, Schilling AF, Peters F, Haag F, Morlock MM, Rueger JM, Amling M (2009):Proinflammatoryandosteoclastogeniceffectsofbeta-tricalciumphosphate and hydroxyapatite particles on human mononuclear cells in vitro. Biomaterials; 2009 Oct; 30(29): 5312–5318.

CERASORB®

Comment:

“1 micron-sized particles of pure β-TCP lead to a lower rate of particle-associated osteoclastogenesis and subsequent particle-induced inflammation and bone resorption than hydroxyapatite particles of the same size.”

2009 Ptosd

Neamat A, Gawish A, Gamal-Eldeen AM (2009): beta-Tricalcium phosphate promotes cell proliferation, osteogenesis and bone regeneration in intrabony defects in dogs. Arch Oral Biol. 2009, 54 (12): 1083–1090.

CERASORB® M

Comment:

“CERASORB® M may induce cell proliferation via induction of PCNA [proliferating cell nuclear antigen] that may induce early osteogenesis and bone formation. CERASORB® M regenerated the bone completely in intrabony defects.”

2009 Ptosd

Pretzsch M, Ebert S, John G, Bader A, Deiwick A, von Salis-Soglio G (2009):Einwachsverhalten von stammzellbesiedelten Knochenersatzkonstrukten bei „critical-size”-Defekten im Kleintiermodell. [Ingrowthbehaviourofbonevoidfillersafterstem-cellcultivationin “critical-size”-defects in a small animal model.] Poster presentation, Deutscher Kongress für Orthopädie und Unfallchirurgie, Berlin, 23.10.2009. Poster in German.

CERASORB®

Comment:

“β-TCP cylinders (10 x 6 mm, curasan AG) could be shown as ideal scaffolds for bone-narrow mesenchymal stem-cells.”

OR

THO

PEDIC

S, TRA

UM

A & SPIN

E

67

SCIEN

TIFIC FU

ND

AM

ENTA

LS

SF67


2008 Ptosd

Handschel J, Berr K, Depprich R, Naujoks C, Kubler NR, Meyer U, Ommerborn M, Lammers L. (2008): Compatibility of Embryonic Stem Cells with Biomaterials. J Biomater Appl. 2008, Aug 29, [Epub ahead of print]. doi:10.1177/0885328208094305, (p. 1–12).


Comment:

“Insoluable collageneous bone matrix followed by β-TCP CERASORB® are the most suitable materials for bone tissue engineering regarding cell proliferation and phenotype. The embryonic stem cells have direct contact with the β-TCP. Especially on CERASORB® M the cells seem to creep into the material.”


2007 Ptosd

Hauschild G, Bader A, Uhr G, Meyer-Lindenberg A, Fehr M (2007): KlinischerEinsatzvonβ-Tricalciumphosphat–Erfahrungenmiteinem matrixorientierten Ansatz zur Osteoregeneration. [Clinicaluseofβ-tricalciumphosphate–experiencewithamatrix-based approach to osseoregeneration.] Tierärztl Prax. 2007, 35 (K): 5–13. Article in German.

CERASORB®

Comment:

“Sceletal defects in 11 dogs were treated with β-TCP CERASORB® to enhance osseoregeneration. In 9 of 11 cases, complete osseous fusion occurred. In 8 cases complete biodegradation of the material became obvious within the observation period.”

2007 Ptos

Reinsch H, Spörl G, Thierfelder A (2007): Einsatz des Knochenaufbaupräparates CERASORB® M als Matrix für das Tissue Engineering.[Use of the bone regeneration material CERASORB® M as matrix for tissue engineering.]Zeitschrift für Regenerative Medizin 2007, 2 (1): 74–83. Article in German.

CERASORB® M

Comment:

“CERASORB® M is suitable as a scaffold for human bone cells in an outstanding matter, whereas by proliferation and secretion of extra-cellular matrix a substantial tissue growth takes place in the scaffold.”

SCIE

NTI

FIC

FU

ND

AM

ENTA

LS

SF68


2007 Ptosd

Schulz J, Pretzsch M, Khalaf I, Deiwick A, Scheidt HA, Salis-Soglio G, Bader A, Huster D (2007): Quantitative Monitoring of Extracellular Matrix Production in Bone Implants by 13C and 31P Solid-State Nuclear Magnetic Resonance Spectroscopy. Calcif Tissue Int. 2007, 80 (4): 275–285.

CERASORB®

Comment:

“Porous cylinders of β-TCP were loaded with osteogenetically differentiated mesenchymal stem cells and implanted into a critical-size defect of the femoral condyle of rabbits. After 3 months, osteogenesis took place and the typical extra-cellular matrix of bone, consisting mostly of inorganic bioapatite and organic collagen was formed.”

2007 Ptosd

Unger RE, Sartoris A, Peters K, Motta A, Migliaresi C, Kunkel M, Bulnheim U, Rychly J, Kirkpatrick CJ (2007): Tissue-like self-assembly in cocultures of endothelial cells and osteoblasts and the formation of microcapillary-like structures on three-dimensional porous biomaterials. Biomaterials 2007, 28: 3965–3976.

CERASORB®

Comment:

“In an in-vitro study, the formation of microcapillary-like structures containing a lumen by human dermal microvascular endothelia cells in coculture with human osteoblast cells and pure-phase β-TCP could be shown.”


2006 Ptosd

Beyen I, Kasten P, Vogel J, Niemeyer P, Luginbühl R, Richter W (2006): Porosityinfluencesosteogenicdifferentiationinvivoandproliferation of mesenchymal stem cells in vitro on beta-tricalcium phosphate solid body scaffolds, but not osteogenic differentiation in vitro. BIOmaterialien 2006, 7 (3): 119. Abstract in English.


Comment:

“The in vivo alkaline phosphatase activity of cell loaded CERASORB® M ceramics was significantly higher compared with two other β-TCP ceramics.”

OR

THO

PEDIC

S, TRA

UM

A & SPIN

E

69

SCIEN

TIFIC FU

ND

AM

ENTA

LS

SF69


2006 Pd

Handschel J, Berr K, Depprich R, Meyer U (2006): Wechselwirkung verschiedener Biomaterialien mit undifferenzierten embryonalen Stammzellen.56. Jahrestagung der Arbeitsgemeinschaft für Kieferchirurgie, Wiesbaden, 25.–27. Mai 2006. Abstract.[Interaction of different biomaterials with undifferentiated embryonal stem cells.]56th Annual Congress of the “Arbeitsgemeinschaft für Kieferchirurgie” (working group for maxillofacial surgery), Wiesbaden, Germany, May, 25–27, 2006. Abstract in German.

CERASORB® M

Comment:

“Of the different biomaterials investigated, the macro porous β-TCP (CERASORB® M) seems to be most suitable as scaffold for embryonal stem cells in bone tissue engineering.”

2006 Pto

Isenberg J, Pearce S, Milz S, Libera J, Köbke J, Josimovic-Alasevic O, Rehm KE (2006):Kritischer Tibiasegmentdefekt – Effekt autologer Osteoblasten auf einemvaskularisiertenβ-TCP-Träger.[Critical size defect of the tibia – Effect of autogenous osteoblasts onavascularizedβ-TCP-scaffold.]Presentation at the “Deutscher Kongress für Orthopädie und Unfallchirurgie”, Berlin, Germany, October 04, 2006. Abstract in German.

CERASORB®

Comment:

“The pilot-study showed the complete degradation of β-TCP-granules within 23 weeks in 4 cm long tibia-segment-defects in adult alpine sheep.”

2006 Ptosd

Friesen K (2006): Proliferations-, Differenzierungs- und Adhäsionsverhalten osteogener Zelllinien auf unterschiedlichen Knochenersatzmaterialien. [Proliferation, differentiation and adhesion behaviour of osteogenic cell lines on different bone substitutes.] Dissertation, Poliklinik für Zahn-, Mund- und Kieferheilkunde, Heinrich-Heine-University, Düsseldorf, Germany 2006: 1–88. Text in German.

CERASORB®

Comment:

“CERASORB® is the only bone graft on which the primary osteoblasts show a significant increase over the total duration of the study.”

SCIE

NTI

FIC

FU

ND

AM

ENTA

LS

SF70


2005 Ptosd

Herten M, Rothamel D, Friesen K, Schwarz F, Becker J (2005): Zelladhäsion und Zelldifferenzierung an verschiedenen Knochenersatzmaterialien. [Cell adhesion and cell differentiation on different bone substitutes.] Poster presentation at the Symposium of the “Arbeitsgemeinschaft für Kieferchirurgie”, 5./6. Mai 2005,Bad Homburg v.d.H./Germany. Abstract in German.

CERASORB®

Comment:“Examined was the influence of different inorganic and xenogenic bone supplements on adhesion, proliferation and differentiation of bone marrow cells, osteoblasts and osteoblast like cells. The cell growth on CERASORB® was significantly higher for all cell types than control.”

2005 Ptosd

Kim CS, Kim JI, Kim J, Choi SH, Chai JK, Kim CK, Cho KS (2005): Ectopic bone formation associated with recombinant human bone morphogenetic proteins-2 using absorbable collagen sponge and beta tricalcium phosphate as carriers. Biomaterials 2005, 26: 2501–2507.

CERASORB®

Comment:

“This study demonstrated that rh BMP-2, when impregnated in ACS and β-TCP provoked osteoinductive activity in rat subcutaneous tissue at two weeks. In addition, histological analysis of rh BMP-2 / β-TCP sites at eight weeks demonstrated the expected normal progression of the bone forming process including Haversian systems and cements lines.”

2005 Ptosd

Kovacs K, Velich N, Huszar T, Fenyves B, Suba Z, Szabo G (2005): Histomorphometric and Densitometric Evaluation of the Effects of Platelet-RichPlasmaontheRemodelingofβ-TricalciumPhosphatein Beagle Dogs. The Journal of Craniofacial Surgery 2005, 16 (1): 150–154.

CERASORB®, PRP

Comment:

“Standardized defects formed in the mandibles of ten beagle-dogs were refilled with β-TCP (CERASORB®) or with a mixture of β-TCP (CERASORB®) and PRP. After twelve weeks, the densitometric and histomorphometric evaluation demonstrated a significant difference in favour of bone substitute used together with platelet-rich-plasma, which accelerates remodeling of β-TCP (CERASORB®) and leads to the formation of hard tissue where the quality is similar to that of autologous bone.”

OR

THO

PEDIC

S, TRA

UM

A & SPIN

E

71

SCIEN

TIFIC FU

ND

AM

ENTA

LS

SF71


2005 Ptosd

Pretzsch M, Wild A, Schulz J, Khalaf I, Zernia G, Deiwick A, Gründer W, Bader A, Huster D (2005): Solid-State NMR Spectroscopy on Bone – First Results and Perspectives. Poster presented on 2nd World Congress on Regenerative Medicine, Leipzig, Germany, 2005.

CERASORB®, block forms

Comment:

“Mesenchymal stem cells were seeded into porous β-TCP (CERASORB®)-cylinders and subsequently implanted into the femoral condyle of rabbits. The stem cells differentiate into osteoblasts and, while new bone material is produced by these cells, β-TCP is partially resorbed.”


2004 Pd

Artzi Z, Weinreb M, Givol N, Rohrer MD, Nemcovsky CE, Prasad HS, Tal H (2004):Biomaterial Resorption Rate and Healing Site Morphology of InorganicBovineBoneandβ-TricalciumPhosphateintheCanine:a 24-month Longitudinal Histologic Study and Morphometric Analysis. Int J Oral Maxillofac Implants 2004 May–Jun, 19 (3): 357–368.

CERASORB®

Comment:

“Complete bone healing was established in all grafted defects. However, at 24 months β-TCP particles were completely resorbed, whereas Inorganic Bovine Bone (IBB) particles still occupied a remarkable area fraction without significant resorption beyond 6 months.”

2004 Pd

Aybar B, Bilir A, Akcakaya H, Ceyhan T (2004): Effects of tricalcium phosphate bone graft materials on primary cultures of osteoblast cells in vitro.Clin Oral Implants Res. 2004 Feb, 15 (1): 119–125.

CERASORB®

Comment:

“The results demonstrate that β-TCP graft material (CERASORB®) has no adverse effect on cell count, viability and morphology, and this material provides a matrix that favours limited cell proliferation.”

SCIE

NTI

FIC

FU

ND

AM

ENTA

LS

SF72


2004 Ptosd

Koepp HE, Schorlemmer S, Kessler S, Brenner RE, Claes L, Günther KP, Ignatius AA (2004):BiocompatibilityandOsseointegrationofβ-TCP:Histomorphological and Biomechanical Studies in a Weight-Bearing Sheep Model. Journal of Biomedical Materials Research 2004, Aug 15, 70B (2): 209–217.

CERASORB®, block forms

Comment:

“It can be concluded that β-TCP block material in a weight bearing implantation model showed good biocompatibility, osseointegration and beginning degradation, even though it was not further degraded between 6 and 12 months.”

2004 Ptd

Kovacs K, Szabo G (2004): [Clinical experience on dental preservation operations applying combinedsyntheticosteogenetics(β-tricalciumphosphate)andplatelet-rich plasma.] Kisallat Praxis 2004, 3: 94–101. Article in Hungarian.

CERASORB®, PRP

Comment:

“Due to the excellent results with beta-tricalcium phosphate (CERASORB®), PRP and their combination in bone reconstruction, this technique should fast spread in small animal veterinary practice.”

2004 Ptosd

Suba Z, Takacs D, Gyulai-Gaal S, Kovacs K, Velich N, Szigeti K, Szabo G (2004): [Alveolar bone regeneration stimulated by a combination of platelet-rich plasma and CERASORB® graft in beagle dogs: Histological and histomorphometric studies.] Fogorv Sz. 2004, 97 (4): 143–149. Article in Hungarian.

CERASORB®, PRP

Comment:

“Bilateral extraction alveoli of the premolars in 12 dogs were filled up with a combination β-Tricalciumphosphate CERASORB® and PRP or CERASORB® alone. After 6 weeks the newly formed bone was significantly denser on the β-TCP/PRP side. After 12 weeks this difference became moderate, after 24 weeks the bone forming activity was nearly equal on both sides. CERASORB® and PRP result in more intense bone regeneration, especially in the early phase.”

2004 Pd

Suba Z, Takacs D, Gyulai-Gaal S, Kovacs K (2004): Facilitationofβ-TricalciumPhosphate-InducedAlveolarBoneRegeneration by Platelet-Rich Plasma in Beagle Dogs: A Histologic and Histomorphometric Study. Int J Oral Maxillofac Implants 2004 Nov–Dec, 19 (6): 832–838.

CERASORB®, PRP

Comment:

“Twenty-four weeks after grafting, bone-forming activity was nearly equal in the two groups (β-TCP with and without PRP), and the bone area in the two groups did not differ significantly (62.9% and 61.9% resp.).”

OR

THO

PEDIC

S, TRA

UM

A & SPIN

E

73

SCIEN

TIFIC FU

ND

AM

ENTA

LS

SF73


2004 Ptosd

Velich N, Kovacs K, Huszar T, Semjen G, Reiczigel J, Szabo G, Suba Z (2004):[The effect of platelet-rich plasma on new bone formation by augmentation with osseoconductive bone substitute material in beagle dogs.] Fogorv Sz. 2004, 97 (1): 23–27. Article in Hungarian.

CERASORB®, PRP

Comment:

“Defects in the mandibles of beagle dogs were filled on one side with β-TCP alone, on the other side with a mixture of β-TCP and PRP (from autologous blood). After 12 weeks new bone formation was significantly greater, when PRP was applied.”


2003 Pd

Aybar B, Günhan Ö, Bilgic L, Emes Y (2003): Guided osteogenesis using synthetic membranes and alloplastic materials: A pilot study.Quintessence Int. 2003, 34 (2): 117–122.

CERASORB®,barriers, membranes

Comment:

“After 6 weeks guided bone regeneration utilizing Gore-Tex augmentation material and TCP (CERASORB®) bone grafts resulted in the formation of viable new bone in calvarian defects in 8 rats.”

2003 Ptosd

Firat D, Özyuvaci H, Oral O, Sirin Y, Utku C (2003): [Acomparativestudyofβ-TCP(CERASORB®) and natural bovine bone mineral (Bio-Oss®) on bone healing in rats.] Cilt5, sayi1, Ocak-Subat-Mart 2003: 28–32. Article in Turkish.

CERASORB®

Comment:

“Symmetrically formed defects in the tibial bone of 21 rats were filled with β-TCP CERASORB® or Bio-Oss®. Microscopic examination revealed the areas filled with CERASORB® showing an increased rate of bone remodeling when compared to Bio-Oss®. Moreover, CERASORB® implanted area resorbs earlier than the Bio-Oss® filled regions in the long term.”

SCIE

NTI

FIC

FU

ND

AM

ENTA

LS

SF74


2003 Ptosd

Kovacs K, Fenyves B, Martonffy K, Semjen G, Szabo G (2003): [Comparative computertomographic (CT) examination of ossificationproducedbythrombocyte-richbloodplasmaandsyntheticbone-substitutematerial(β-tricalcium-phosphate).]Magyar Allatorvosok Lapja 2003, September: 537–542. Article in Hungarian.

CERASORB®, PRP

Comment:

“Bone regeneration was more effective (in the beagle dog) when thrombocyte suspension and β-TCP were applied simultaneously than the single application of β-TCP.”

2003 Pd

Kovacs K, Velich N, Huszar T, Szabo G, Semjen G, Reiczigel J, Suba Z (2003):ComparativeStudyofβ-TricalciumPhosphateMixedwithPlatelet-richPlasmaversusβ-TricalciumPhosphate,abonesubstitute material in dentistry. Acta Veterinaria Hungarica 2003, 51 (4): 475–484.

CERASORB®, PRP

Comment:

“Two teeth were removed symmetrically from each side of the mandible of 12 Beagle dogs; the resulting cavities were filled on one side with β-TCP alone, on the other side with a mixture of β-TCP and PRP (from autologeous blood). In week 12 new bone formation was significantly greater, when PRP was applied.”

2003 Pd

Kovacs K, Szabo G (2003): [Cystectomyandfillingofcystcavitywithbonesubstituteβ-tricalciumphosphate(CERASORB®) in dogs. Case report.] Magyar Allatorvosok Lapja 2003, 125 (4): 225–228. Article in Hungarian.

CERASORB®

Comment:

“In the treatment of a non-erupted first premolar mandibular tooth (of a dog) the osteoinductive bone substitute β-TCP (CERASORB®) was used, which is rarely used in veterinary medicine so far. This substance may be useful for bone substitution in small animal practice.”

2003 Pd

Merten HA, Gruber RM, Nitsch A, Ludwig A, Schliephake H (2003): Evaluation oralchirurgischer Augmentationsmaterialien – Ein tierexperimentell-histomorphologischer Vergleich. [Evaluation of augmentative materials in oral surgery – A histomorphometric comparison in animals.] Implantologie 2003, 11 (3): 215–236. Abstract in German.

CERASORB®

Comment:

“CERASORB® is “golden standard” among the bone regeneration materials.”

OR

THO

PEDIC

S, TRA

UM

A & SPIN

E

75

SCIEN

TIFIC FU

ND

AM

ENTA

LS

SF75

CERASORB® & CERACELL®– 2002Year Legend Literature Products

2002 Ptosd

Wiltfang J, Merten HA, Schlegel KA, Schultze-Mosgau S, Kloss FR, Rupprecht S, Kessler P (2002): DegradationCharacteristicsofαandβTri-Calcium-Phosphate(TCP) in Minipigs. J Biomed Mater Res. 2002, 63: 115–121.

CERASORB®

Comment:

“The β-TCP material shows an accelerated degradation mode and has an optimal reactivity with the surrounding tissues. Compared to α-TCP the smaller-dimensioned β-TCP granules led to a finer architecture of the newly formed bone trabeculae, resulting in an early biofunctional adaptation of the bone substitute during the regeneration process.”


2001 Pd

Merten HA, Wiltfang J, Grohmann U, Hoenig JF (2001): IntraindividualComparativeAnimalStudyofα-andβ-TricalciumPhosphate Degradation in Conjunction with Simultaneous Insertion of Dental Implants. J Craniofac Surg. 2001: 12 (1): 59–68.

CERASORB®

Comment:

“The interconnecting microporosity of the investigated special β-TCP, which should be no smaller than 5 µm, resulted in faster degradation and micro-osseous conduction, and exhibited better tissue response toward the ceramic in comparison with α-TCP.”

2001 P TCto

WolfK,HamarJ,MoravecS,FarkasT,HöcherlE,PfisterC(2001): Analysis of the Morphology of Intergranular Porosity of β-TricalciumPhosphateinRelationtoDevelopmentofVasculoneogenesis in an Animal Experiment and Overview of the Indicationsforβ-TricalciumPhosphateinHumanPatients.Applied Cardiopulmonary Pathophysiology 2001, 10 (2): 3–12.

CERASORB®, PRP

Comment:

“β-tricalcium phosphate is a useful implant material that encourages healing of bony defects and fractures. In keeping with the qualities required of a bone substitute, this material fulfills the role of a placeholder, forms a guide rail for osteogenesis and serves as a mineral depot.”

SCIE

NTI

FIC

FU

ND

AM

ENTA

LS

SF76


2001 Ptd

Soost F (2001): Validierung des Knochenumbaus von Knochenersatzmaterialien in der Mund-, Kiefer- und Gesichtschirurgie. [Validation of the transformation of bone replacement materials in the oral and maxillo-facial surgery.] Professional Dissertation, Free University Berlin. 06.03.2001,P. 60–61. Written in German.

CERASORB®

Comment:

“Regarding the increase of the bone metabolism activity, the time-activity-curves of autogenous spongiosa and CERASORB® are equally.”


2000 Ptod

Merten HA, Hönig JF, Krantz C, Wiltfang J (2000): Histomorphologische Untersuchungen zum Resorptionsverhalten phasenreinerβTCP-KeramikenimTibiadefektdesadultenMinipigs. [Histomorphological examinations on the resorption of pure-phaseβTCPceramicsintibiadefectsintheadultmini-pig.]Osteosynthese International 2000, 8 (Suppl. 1): 107–110. Article in German.

CERASORB®

Comment:

“Within 15 to 18 months CERASORB®, the pure-phase β-TCP ceramic, is entirely substituted by bone in an artificial marrow canal defect and, in an ideal way fulfills the requirements placed on an osteo-potent bone regeneration material.”

2000 Pto

Merten HA, Ludwig A, Wiltfang J, Hönig JF (2000): Protegierte knöcherne Regeneration von klinisch relevanten TibiadefektenmitphasenreinerβTCP-KeramikbeimadultenMinipig.[Bony regeneration of tibia defects with clinical relevance with pure-phaseβTCPceramicintheadultmini-pig.]Osteologie 2000, 9 (Suppl. 1): 40. Article in German.

CERASORB®

Comment:

“Within 68 weeks CERASORB®, a pure-phase β-TCP ceramic is completely degraded and substituted by bone. Histologically, RES-contamination with ceramic particles can be excluded. Clinically, the β-TCP ceramic CERASORB® can be recommended for the filling of bone defects.”

OR

THO

PEDIC

S, TRA

UM

A & SPIN

E

77

SCIEN

TIFIC FU

ND

AM

ENTA

LS

SF77


2020 PMTCtos

Peters F, Bahrini K, Placht AM, Gelinsky M (2020):Beladung und kontrollierte Freisetzung von Antibiotika aus Bio-materialien für die Knochenregeneration. [Loading and controlled release of antibiotics from biomaterials for bone regeneration.]OUP 2020; 9 (1). Article in German.

CERASORB® M,CERASORB®

Foam

Comment:

“The results of in vitro loading tests and release kinetics of various antibiotics (vancomycin, gentamicin, meropenem) from CERASORB® granules and CERASORB® Foam are presented. An important aspect is the minimum inhibitory concentration (MHK or minimum inhibitory concentration, MIC), i. e. the minimum concentration of the active substance, which must be on site in order to achieve antibacterial activity. Commercially available antibiotic preparations can be mixed with the biomimetic bone regeneration materials of the CERASORB® product range. It turns out that both the loading capacity of the materials as well as the release kinetics, the concentration of active ingredients over time, in the environment of the biomaterials are always above the MHK and below the toxic limit.”

2020 TCM o

Busch A, Herten M, Haversath M, Kaiser C, Brandau S, Jäger M (2020):Ceramic scaffolds in a vacuum suction handle for intraoperative stromal cell enrichment.Int J Mol Sci, 2020 Sep 2;21(17):6393. doi: 10.3390/ijms21176393.

CERASORB® M

Comment:

“A surgical vacuum suction handle was filled with either bone substitute granules (CERASORB® M) or cancellous allograft, both acting as a filter to harvest cell-tissue composites (CTC). The study investigated the osteopromotive potential of CTC trapped in the bone substitute filter material during surgical suction in 10 elective total hip and knee replacement surgeries. Mononuclear cells (MNC) were isolated from the CTC and investigated towards cell proliferation and colony forming unit (CFU) formation; mesenchymal stromal cells (MSCs) were examined for surface markers, and the presence of defined cytokines for stimulation of cell proliferation and differentiation. Relevant numbers of MSCs and cytokines qualified for bone regeneration were found in the allograft and CERASORB® M granules. No significant differences could be found in the capability to enrich MSCs and growth factors. Neither biomaterial-associated differences for the amount of MNC harvested nor variations in the stemness character of the cells (number of CFU) were found.”

SCIE

NTI

FIC

FU

ND

AM

ENTA

LS

SF78


2019 PMDCd

Lee D, Choi EJ et al. (2019):Injectablebiodegradablegelatin-methacrylate/β-tricalcium phosphate composite for the repair of bone defects.Chemical Engineering Journal 365 (2019) 30-39.

CERASORB® M

Comment:

“The chemical and physical properties of a prepared gelatin/methacrylic anhydride composite (GelMA) and a composite with GelMA hydrogel incorporating β-TCP (CERASORB® M) (GelMA-B) GelMA-B are reported. The gelatin-methacrylate (GelMA) hydrogel was applied into the β-TCP to produce a GelMA/β-TCP composite (GelMAB). This reinforced the mechanical strength and regulated the absorption period of β-TCP. To characterize the physical properties of the formed composite, GelMA-B was tested using a mechanical tester and a rheometer; biocompatibility, osteogenic differentiation was assessed and bone regeneration in an animal study tested. GelMA-B showed higher mechanical strength than β-TCP and GelMA alone. GelMA-B maintained its volume and shape during regrowth.


2009 Mtod

Hänel T, Peters F, Hoffmann C, Dürr H (2009): Aus CT-Daten generierte patientenindividuelle Implantate aus β-TricalciumphosphatfürdieKnochenregeneration.[Patientindividualβ-TCPimplantsforboneregenerationgenerated from CT-data.] Regenerative Medizin 2009, 2 (1): 13–17. Article in German.

CERASORB®

block forms

Comment:

“Individual implantable biomaterials as ready-to-use product, which is fast, direct and true to size implantable in a bone defect, are a further step in the development of easy and riskless bone regeneration.”

2009 Mtosd

Peters F, Hübner WD (2009): BoneRegenerationwithβ-TricalciumPhosphate:NewAspects.In: Kossler W, Fuchs J: Bioceramics (2009): Properties, Preparation and Applications. Pages 265–275.


Comment:

“Review on 40 years research and development of β-tricalciumphosphate and CERASORB®.”

OR

THO

PEDIC

S, TRA

UM

A & SPIN

E

79

SCIEN

TIFIC FU

ND

AM

ENTA

LS

SF79


2006 Mtosd

Ermrich M, Peters F (2006): X-raypowderdiffractiondataofsyntheticβ-TricalciumPhosphate– Röntgenpulverdiffraktometrische Daten von synthetischem β-Tricalciumphosphat.Mat.-wiss. u. Werkstofftech. 2006, 37 (6): 526–529. Article in English.

CERASORB®

Comment:

“The production of synthetic tricalcium phosphate (β-TCP) allows excluding all disadvantages of biologically based ceramics. Moreover, the sintered pure-phase material ensures a high reproducibility without any organic residues of foreign matters.”

2006 Md

Peters F, Groisman D, Davids R, Hänel Th, Dürr H, Klein M (2006): ComparativeStudyofpatientindividualimplantsfromβ-tricalciumphosphate made by different techniques based on CT data. Mat.-wiss. u. Werkstofftech. 2006, 37 (6): 457–461.

CERASORB®,CERASORB® M,granules/ block forms, CERASORB® Perio/ParoComment:

“Especially defects where surgeries have a longer planning horizon can be treated with custom-made patient individual implants. Two different techniques for making such implants from β-TCP with 3-dimensional fabrication methods were experimentally realised and estimated.”


2005 Mtosd

Peters F, Hniopek T, Hasanovic K (2005): Mechanische Charakterisierung von granulären Knochenersatzmaterialien.[Mechanical characterization of granular bone substitutes.] Biomaterialien 2005, 6 (3): 244 (Poster). Poster in German.


Comment:

“Abrasion tests showed that the fine particles spectra are far away from the area which underlays phagocytosis. This shows that the material has no risk for an inflammation of the surrounding soft tissue in case of mechanical disintegration.”

SCIE

NTI

FIC

FU

ND

AM

ENTA

LS

SF80


2004 Mto

Hauschild G, Bader A (2004): Vor- und Nachteile synthetischer versus xenogener Knochenersatzmaterialien.[Advantages and disadvantages of synthetic versus xenogen bone grafts.]Tierärztliche Praxis Kleintiere 2004, 32: 67–70. Article in German.

CERASORB®

Comment:

“Due to the risk of possible transmission of prions causing bovine spongiform encephalopathia and Creutzfeld-Jakob Disease by using xenografts based on bovine material and with a view to its osteoinductive power, synthetic bone regeneration materials of pure phase β-TCP are a reasonable alternative.”

2004 Mtosd

Peters F, Reif D (2004): Functional Materials for Bone Regeneration from Beta-Tricalcium Phosphate.Funktionelle Materialien zur Knochenregeneration aus Beta-Tricalciumphosphat.Mat.-wiss. u. Werkstofftech. 2004, 35 No. 4: 203–207. Article in English.

CERASORB® granules/ block forms, CERASORB® M, CERASORB® Paro/Perio

Comment:

“β-TCP bioceramics have remarkable differences. Today different morphologies of the synthetic β-TCP bone regeneration material CERASORB® for different applications are available for reaching the goal of complete bone regeneration.”

2004 Mtosd

Tadic D, Epple M (2004): A thorough physicochemical characterisation of 14 calcium phosphate-based bone substitution materials in comparison to natural bone. Biomaterials 2004, 25 (6): 987–994.

CERASORB®

Comment:

“14 different bone graft materials were investigated and the results were compared to synthetic hydroxy-apatite and natural bone samples… CERASORB® is the only phase pure β-TCP of the tested β-TCP’s.”

81

Dentistry2019 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 82

2018 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 82

2017 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 83

2015 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 84

2013 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 84

JEDER®

Explanation

Abbrev.: Meaning:


d Dentoalveolar and OMF surgery

CO

NTEN

T

DEN

TIST

RY

82

JEDER® – 2019Year Legend Literature Products

2019 DCd

Foitzik J (2019):Minimalinvasiver Sinuslift nach JEDER – ein Erfahrungsbericht. [Minimally invasive sinus lift according to JEDER – a case report.] Implantologie Journal 12, 2019.

JEDER® System, CERASORB® M

Comment:

“The article describes the experience with JEDER® System for the transcrestal sinus lift in combination with CERASORB® Paste in about 60 cases within 2 years. On the basis of this experience, sinus floor elevation according to JEDER® can be recommended without restriction as a reliable minimally invasive method for bone augmentation in the upper jaw side tooth area. No side effects or complications are reported. A case of a multi-chambered maxillary sinus in region 26 with a clear bony septum and insufficient vertical bone for an implant insertion is presented.”


2018 DCd

Bruckmoser E, Gruber R, Steinmassl O, Eder K, Watzinger F, Bayerle-Eder M, Jesch P (2018): Crestal Sinus Floor Augmenta-tion Using Hydraulic Pressure and Vibrations: A Retrospective Single Cohort Study. Int J Oral Maxillofac Implants. 2018 Sep/Oct;33(5):1149-1154. doi: 10.11607/jomi.6478.

JEDER® System

Comment:

“This retrospective, single center clinical investigation shows that minimal invasive crestal sinus augmentation using the JEDER® System can be done with a sinus membrane perforation rate of less than 10% and an implant survival rate of appr. 90%. 149 patients had undergone in total 184 crestal sinus floor augmentations between 2007 and 2015. The cumulative implant survival rates after 1, 3, and 5 years were 94.4%, 87.7%, 87.7%. No severe perioperative complications (like severe hemorrhage, massive swelling, allergic reaction) were noted. 10 perforations were observed (8.9%).”

DEN

TISTRY

83


2018 DCd

van Orten A (2018): Minimalinvasive Sinuslift-Techniken - Der minimalinvasive Sinuslift mit dem Jeder-System. [Minimally inva-sive sinus lift techniques - The minimally invasive sinus lift with the JEDER® system.] Dentale Implantologie, Mai 2018, 22 (3): 174-179.

JEDER® System

Comment:

“The Author provides a short summary about sinus lift technologies in general, followed by a description of the JEDER® System work flow and the application of the technology in 3 patient cases. He recommends as pre-requisite for the technology a residual bone height of 0.5 to 7 mm and an alveolar ridge width of 5.5 mm to allow for a 2 mm in diameter pilot bore.”


2017 DCd

Eder K (2017): Maximaler Knochenaufbau mit minimalinvasivem Sinuslift. Weniger postoperative Probleme. [Maximum bone for-mation with minimally invasive sinus lift. Less post-operative problems.] BDIZ EDI konkret 02.2017: 110-112 and Zahn Krone 6/2016: 40-42.

JEDER® System

Comment:

“The authors report on an uneventful case of a 63-year-old man in whom 3 sinus lift interventions were performed at one time. The bone height in this patient was elevated on average by 11 mm from 3.3 mm to 14.8 mm. 4.5 ml of bone graft was implemented. The patient was very satisfied (rank 9 of 10). No postoperative complications like hematoma or swelling. The authors emphasize that the JEDER® system allows for an even and optimal pressure distribution for lifting the sinus membrane.”

DEN

TIST

RY

84


2015 DCd

Engelschalk M (2015): Minimalinvasiver Sinuslift mit hohem hydraulischen Druck – eine Multicenter-Pilotstudie. [Minimally invasive sinus lift with high hydraulic pressure – a multicenter pilot study.] Oralchirurgie Journal 3, 2015: 24-27. Article in German.

JEDER® System

Comment:

“The initial 18 patients included into the safety and efficacy study by Jesch et al in 2013 were followed up over an 18-month period. 19 out of the 20 implants (95%) were fully functional after 18 months. The average patient satisfaction (10 rank scale) was 99.8. The residual bone height 4.6 ± 1.4 mm.”


2013 DCd

Jesch P, Bruckmoser E, Bayerle A, Eder K, Bayerle-Eder M, Watzinger F (2013): A pilot-study of a minimally invasive tech-niquetoelevatethesinusfloormembraneandplacegraftforaugmentation using high hydraulic pressure: 18-month follow-up of 20 cases. Oral Surg Oral Med Oral Pathol Oral Radiol. 2013 Sep;116(3):293-300. doi: 10.1016/j.oooo.2013.05.014.

JEDER® System

Comment:

“This was the first study to evaluate efficacy and safety of transcrestal, minimally invasive sinus floor augmentation based on high hydraulic pressure using the JEDER® System. Twenty interventions were performed in 18 patients at 2 study sites in Vienna, Austria. The publication describes the components and function of the JEDER® System, i.e. the JEDER® drill, the JEDER® pump, and the connecting tubeset. Only in one case (1/20, 5%) a membrane perforation was detected in the postoperative computed tomography scan and without implication for implant placement was observed. Bone height gain of 9.2 ± 1.7 mm was achieved (from 4.6 ± 1.4 mm to 13.8 ± 2.3 mm). Average patient satisfaction was 9.82 on scale from 1 to 10 (10 = very satisfied). Mean duration of sick leave was 0.19 days.”

85

CO

NTEN

T

Orthopedics & SpineKnee

2014 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 87

2011. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 88

2010 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 89

2009 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 89

2008 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 90

Hip

2008 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 90

Shoulder

2011 ......................................................88

2008......................................................90

Facet joint

2014 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 86

2012 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 86

2010......................................................86

2009......................................................87

2008......................................................90

Ankle joint (upper / lower)

2011. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 88

2008 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 90

Thumb / carpometacarpal joint

2011. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 90

2010 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 91

Curavisc®

Explanation

Abbrev.: Meaning:

kn Knee

h Hip

sh Shoulder

f Facet joint

a Ankle joint (upper / lower)

th Thumb / carpometacarpal joint

OR

THO

PED

ICS

& S

PIN

E

86

Curavisc® – 2014Year Legend Literature Products

2014 f Keller H (2014): Die Behandlung der Facettengelenkarthrose mit Hyaluronsäure. [Treatment of facet joint arthropathy with hyaluronic acid.] OUP 2014; 10: 484–489. DOI 10.3238/oup.2014.0484–0489. Article in German, Abstract in English.

Curavisc®

Comment:

“The treatment with the hyaluronic acid product Curavisc® was very well tolerated by all patients and was very effective in nearly 90% of the patients, especially when the degenerative complaints were not so much expressed at the beginning of the disease.”


2012 f Keller H (2012): Die Behandlung der Facettengelenksarthrose mit Hyaluronsäure. [Treatment of facet joint arthropathy with hyaluronic acid.] Chirurgenmagazin 2012, 57, Ausgabe 3.2012. Article in German.

Curavisc®

Comment:

“The treatment was very effective. Especially remarkable is that the improvement continued in most patients after the treatment period – and the treatment success even increased during the follow-up.”


2010 f Keller H (2010): Die Behandlung der Facettengelenke mit Hyaluronsäure – Posterpräsentation P18. [Treatment of the Facet Joints with Hyaluronic Acid – poster presentation P18.] Poster presentation, 58th Annual Meeting of „Vereinigung Süddeutscher Orthopäden e.V” in Baden-Baden, Germany, April 29–May 2, 2010. Abstract in German.

Curavisc®

Comment:

“80 consecutive out-patients were treated with three injections of Curavisc® at weekly intervals. 37% reported complete freedom of symptoms, 49% significant improvement.”

OR

THO

PEDIC

S & SPIN

E

87


2009 f Keller H (2009): Treatment of the Facet Joint Syndrome with Hyaluronic Acid – Poster P146. Poster presentation on “4. Deutscher Wirbelsäulenkongress” (4th Annual Meeting of the German Spine Association) in Munich, Germany, December 10–12, 2009. Abstract in: Eur Spine J 2009, 18: 1798.

Curavisc®

Comment:

“The intra-articular injection treatment with hyaluronic acid seems to be an uncomplicated, clinically effective and enduring alternative to systemic or topical anti-inflammatories or anti-rheumatics in the treatment of the facet syndrome.”


2014 kn Schneider S, Zahn T, Springorum H-W, Schofer M (2014): BeeinflussungvonFunktions-undSchmerzparameterndurchintraartikulär applizierte Hyaluronsäure nach Kniearthroskopie. [Influenceofpost-arthroscopicintra-articularadministeredhyaluronic acid on parameters of function and pain in the knee.] OUP 2014; 7: 333–339. DOI 10.3238./oup.2014.0333–0339. Article in German, Abstract in English.

Curavisc®

Comment:

“The present study could show that immediately post arthroscopic application of hyaluronic acid (Curavisc®) caused a reduction of pain and a measurable improvement of quality of life for the patients regarding function and exercise capacity.”

OR

THO

PED

ICS

& S

PIN

E

88


2011 kn Schneider S, Zahn T, Springorum H-W (2011): Intraartikulär applizierte Hyaluronsäure nach Kniearthroskopie – Vortrag 04.11. [Intraarticular application of hyaluronic acid after knee arthroscopy–lecture 04.11.] Lecture on June 18, 2011, 60th Annual Meeting of „Norddeutsche Orthopäden- und Unfallchirurgenvereinigung e.V.“ in Hamburg, Germany, June 16–18, 2011. Abstract in German in: Der Unfallchirurg 2011, 114 (Suppl. 2): 21.

Curavisc®

Comment:

“The post-operative pain score was always lower in the hyaluronic acid treatment group compared to the control group. A clear significance was given regarding the maximum walking distance.”

2011 kn Träger SJ, Degenhart M (2011): Stadienabhängiger Langzeitverlauf nach Hyaluronsäureapplikation bei Gonarthrose – Vortrag 04.08. [Stage adjusted long-term course after hyaluronic acid application in gonarthritis – lecture 04.08.] Lecture on June 18, 2011, 60th Annual Meeting of “Norddeutsche Orthopäden- und Unfallchirurgenvereinigung e.V.“ in Hamburg, Germany, June 16–18, 1011. Abstract in German in: Der Unfallchirurg 2011, 114 (Suppl. 2): 19–20.

Curavisc®

Comment:

“Knee joints with minor or moderate cartilage damages showed the longest-running improvement after five Curavisc® injections at weekly intervals.”

2011 knsha

Weinhart H (2011): Therapeutischer Effekt von intraartikulär applizierter Hyaluronsäure – eine Langzeitbeobachtung über 5 bis 10 Jahre mit > 4 Wiederholungsserien – Vortrag 77.01. [Therapeutic effect of intraarticular applied Hyaluronic Acid – Long term monitoring over 5 to 10 years with > 4 treatment courses – lecture 77.01.] Lecture on June 18, 2011, 60th Annual Meeting of „Norddeutsche Orthopäden- und Unfallchirurgenvereinigung e.V.“ in Hamburg, Germany, June 16–18, 2011. Abstract in German in: Der Unfallchirurg 2011, 114 (Suppl. 2): 109–110.

Curavisc®

Comment:

“The injection therapy with Curavisc® seems to be a less harmful and sustainable alternative in the long-term treatment of osteoarthritis with improved quality of life and maintaining mobility.”

OR

THO

PEDIC

S & SPIN

E

89


2010 kn Zahn T (2010): ProspektiveUntersuchungderBeeinflussungvonEntzündungs-und Schmerzparametern durch intraartikulär applizierte Hyaluronsäure – Vortrag P72. [Prospectiveobservationoftheinfluenceofintraarticularappliedhyaluronicacidonparametersofinflammationandpain.]Poster presentation, 58th Annual Meeting of „Vereinigung Süddeutscher Orthopäden e.V.“ in Baden-Baden, Germany, April 29–May 2, 2010. Abstract in German.

Curavisc®

Comment:

“Curavisc® could show its efficacy after knee joint arthroscopy as well as regarding the reduction of pain and well-being.”


2009 kn Zahn T (2009): ProspektiveUntersuchungderBeeinflussungvonEntzündungs-und Schmerzparametern durch intraartikulär applizierte Hyaluronsäure nach Kniearthroskopie – Vortrag P63. [Prospectiveobservationoftheinfluenceofintraarticularappliedhyaluronicacidonparametersofinflammationandpainafterarthroscopy of the knee-joint.] Poster presentation on June 18, 2009, 58th Annual Meeting of „Norddeutsche Orthopädenvereinigung e.V.” in Hamburg, Germany, June 18–20, 2009. Abstract in German.

Curavisc®

Comment:

“The post-operative pain rating was lower for all items in the Curavisc® group compared to the placebo group.”

OR

THO

PED

ICS

& S

PIN

E

90


2008 knhshaf

Weinhart H (2008): Treatment of Degenerative Joint Disease with the Hyaluronic Acid Product Curavisc®. Post-marketing surveillance study of safetyandefficacy.[Behandlung von Arthrosen mit dem Hyaluronsäure-Produkt Curavisc® – Anwendungsbeobachtung zur Sicherheit und Wirksamkeit.] Orthopädische Praxis 2008, 44, 1, 37–43. English reprint of German Article.

Curavisc®

Comment:

“525 patients were treated with 5 injections each. Curavisc® proved to be a very well-tolerated and clinically effective alternative to systemically or locally applied antiphlogistics or antirheumatic agents in the treatment of mild to moderate osteoarthritis of synovial joints.”

2008 kn Zahn T (2008): ProspektiveUntersuchungderBeeinflussungvonEntzündungs-und Schmerzparametern durch intraartikulär applizierte Hyaluronsäure nach Kniearthroskopie. [Perspectivestudyontheimpactoninflammatoryandpainparameters by the intraarticular application of hyaluronic acid after knee arthroscopy.] Dissertation, Medizinische Fakultät Heidelberg, Germany, 2008, Text in German.

Curavisc®

Comment:

“The placebo-controlled study with 100 patients showed that Curavisc® had a significant effect on the subjective pain of the treated patients.”


2011 th Talke M (2011): Die Behandlung der Daumensattelgelenksarthrose mit Hyaluronsäure – Vortrag 45.09. [Treatment of rhizarthritis with hyaluronic acid – lecture 45.09.] Lecture on June 18, 2011, 60th Annual Meeting of „Norddeutsche Orthopäden- und Unfallchirurgenvereinigung e.V.” in Hamburg, Germany, June 16–18, 2011. Abstract in German in: Der Unfallchirurg 2011, 114 (Suppl. 2): 76–77.

Curavisc®

Comment:

“The injection therapy with Curavisc® is not only successful during the treatment cycle. At least during the follow-up period over six months an improvement of the symptoms could be observed.”

OR

THO

PEDIC

S & SPIN

E

91


2010 th Talke M (2010): Behandlung der Arthrose des Daumensattelgelenkes mit dem Hyaluronsäure-Produkt Curavisc® mini. Offene, prospektive, monozentrische Studie. [Treatment of rhizarthritis with the hyaluronic acid product Curavisc® mini – open prospective monocentre study.] Orthopädische Praxis 2010, 46 (9): 443–451. Article in German, Abstract in English.

Curavisc®

Comment:

“30 patients with rhizarthritis showed good to satisfactory outcomes after three injections with Curavisc®.”

2010 th Talke M (2010): Die Behandlung der Daumensattelgelenksarthrose mit Hyaluronsäure – Vortrag W28.6. [Treatment of rhizarthritis with hyaluronic acid.] Lecture on April 30, 2010, 58th Annual Meeting of „Vereinigung Süddeutscher Orthopäden e.V.“ in Baden-Baden, Germany, April 29–May 2, 2010. Abstract in German.

Curavisc®

Comment:

“In not progressed stages of osteoarthritis of the thumb saddle joint the injection therapy with Curavisc® is a less harmful and sustainable alternative treatment.”

92

Dentistry2019 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 93

2015 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 93

2009 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 94

2005 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 94

2004 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 95

2003 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 95

Orthopedics, Trauma & Spine2016 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 96 2005 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 96

General Surgery2018 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 97

2014 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 98

2003 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 98

Scientific Fundamentals2013 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 99 2000 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 99

GC

SF

stypro®

Explanation

Abbrev.: Meaning:

M MaterialScientific/FundamentalResearch

P Preclinic / in-vitro and in-vivo study


TC Clinic – Traumatology / Orthopedics / Spine

GC Clinic – General Surgery

CO

NTE

NT

DEN

TISTRY

93

stypro® – 2019Year Legend Literature Products

2019 DC Palm F, Rupp J, Götz W (2019): Experiences with a collagen composite in socket preservation. implants 2019, 4: 14-18.

stypro®

Comment:

“A split-mouth clinical study with 35 patients was designed to evaluate the performance of CERASORB® Foam in socket preservation procedures. As a comparative material, a gelatine haemostatic sponge (stypro®, curasan) was chosen owing to similarities in the application techniques of both products. The publication presents two cases out of the study; one case of a patient with after severe periodontal disease affecting the bone and another case of alveolar ridge preservation with five teeth extracted. The healing in the CERASORB® Foam group was as good as the healing in the stypro® group. Both materials stabilised the haematoma, which was very good for the healing process. However, the bone loss in the stypro® group was significantly higher than in the CERASORB® Foam group.”


2015 DC Salahi S, Etemadifar R, Moosaali F (2015):Morphometric changes of the socket after site preservation using Nanobone and collagen membrane or stypro® versus extraction alone. J Dent Biomater, 2015; 2 (2): 54-60.

stypro®

Comment:

“The study evaluates morphometric changes after different alveolar ridge preservation procedures in 33 patients who had single-rooted premolar, which needed to be extracted. 3 groups: group A: NanoBone® (nanocrystalline HA/Artoss) and a collagen membrane; in group B: NanoBone® and stypro®; and in group C: natural healing. The use of collagen membrane+Nanobone® (group A) can significantly reduce the horizontal resorption of the alveolar ridge and keratinized tissue more effectively than stypro®+Nanobone® (group B) and blood clot alone andnatural healing (group C).”

DEN

TIST

RY

94


2009 DC Shakibaie-M B (2009): Socket and ridge preservation from the three-dimensional perspective – A clinical study. Z Zahnärztl Im-plantol. 25. Jahrgang / Heft 4/2009, 369–377. Translated original study. Translation in English.

stypro®

Comment:

“Sockets were filled with bovine bone graft and covered with stypro® or with stypro® alone. Alveolar ridge width and height could be preserved better in the study group than in the control group.”

2009 DC Zhao D, Wang J (2009): Clinical observation for hemostasis sponge to prevent the dry socket. China Medical Herald, Editorial E-mail, 2009 (02) [2009-01-15]. Article in Chinese, Abstract in English.

stypro®

Comment:

“The hemostasis sponge (stypro®) can prevent effectively the dry socket occurring post extraction of the third molar.”


2005 DC Doumat A, Wefers H, Wefers K (2005): Der Einsatz eines Gelatineschwammes in der Mund-, Kiefer- und Gesichtschirurgie. [On the application of a gelatine sponge in the maxillo-facial surgery.] Implantologie Journal 2005, 2: 19–22. Article in German.

stypro®

Comment:

“Using stypro® in heavily bleeding operation areas brings a huge time advantage, as other time-consuming stopping bleeding measures can be avoided in most cases.”

DEN

TISTRY

95


2004 DC Broos B (2004): Unterstützende Maßnahmen beim internen Sinuslift zum Schutz der Kieferhöhlenschleimhaut (Schneidersche Membran). [Supportive measures to protect the Schneiderian membrane in internal sinus lift procedures.]Implantologie Journal 2004, 7: 47–48. Article in German.

stypro®

Comment:

“The application of stypro® supports the bone regeneration and the osseous integration of the implants. Process related complications were not observed.”


2003 DC Pape HD (2003): Indikation und Anwendung von stypro® in der Lippen-Kiefer- Gaumenspaltchirurgie. [Indication and application of stypro® in cleft-lip-palate surgery.] Implantologie Journal 2003, 7 (1): 52–54. Article in German.

stypro®

Comment:

“When stypro® was used, no secondary bleeding was observed. There were no wound infections or disorders of wound healing.”

OR

THO

PED

ICS,

TR

AU

MA

& S

PIN

E

96


2016 TC Xu D, Ren Z, Chen X, Zhuang Q, Sheng L, Li S (2016):A randomized controlled trial on effects of different hemostatic sponges in posterior spinal fusion surgeries. BMC Surg. 2016 Dec 12; 16 (1): 80.

stypro®

Comment:

“Three different hemostatic sponges were tested in posterior spinal fusion surgeries. stypro® demonstrated the best hemostasis effect, the slowest postoperative drainage volume. In the first 24 h, the drainage volume of patients in Group A (stypro®) and B is significantly smaller, as well as total postoperative volumes of drainage (p < 0.05) during their hospital stay. The drainage volumes in the second 24 h were similar in the 3 groups. The average drainage Hematocrit (HCT) reduced over time, the average HCT of drainage is 18.04% and 11.72% on the first day and on the second day respectively for group A, which was lowest amongst the 3 groups.”


2005 TC Geldbach J, Springorum HW (2005): Pilotstudie zur Vergleichbarkeit eines Fertigproduktes mit einem perioperativ mit einem Antibiotikum beladenen Gelatineprodukt. [Pilotstudytocompareafinishedproducttoaperi-operativelywith gentamicin loaded gelatine product.] Poster presentation P17, 176th Meeting of „Vereinigung Nordwestdeutscher Chirurgen“, Hamburg, Germany, December 2, 2005. Poster in German.

stypro®

Comment:

“10 patients each were treated with a commercially available gentamicin containing combination product, the other 10 with the gelatine sponge stypro® loaded intra-op with gentamicin. The clinical evaluation showed, that there was no difference between the two study groups regarding clinical efficacy and lab results, thus opening up significant savings potentials in orthopaedic, trauma, and general surgery.”

GEN

ERA

L SUR

GERY

GC97


2018 GC Awada H, Geller JC, Brunelli M, Ohlow MA (2018): Pocket related complications following cardiac electronic device implantation in patients receiving anticoagulation and/or dual anti-platelet therapy: prospective evaluation of different preventive strategies. J Interv Card Electrophysiol. 2019 Apr;54(3):247-255. doi: 10.1007/s10840-018-0488-y. Epub 2018 Nov 21.

stypro®

Comment:

“The safety and effectiveness of three different devices: (1) vacuum drainage system, (2) hemostatic gelatin sponge (stypro®), and (3) compression device (Premofix®) compared to standard of care (control) was assessed in patients undergoing cardiac implantable electronic device (CIED) implantation receiving anticoagulation and/or dual antiplatelet therapy (DAPT). 406 patients (median age 73 years, 71% male) of whom 103 (25%) received a vacuum drainage system, 99 (24%) received stypro®, 103 (25%) received Premofix®, and 101 (25%) were in the control group. One hundred eighty patients (44%) were treated with anticoagulation (median INR 2.0), 176 (43%) received DAPT, and 50 (12%) both. The occurrence of the primary end point of hematoma and pocket infection was reduced by stypro® (hazard ratio (HR) 0.38 (95% confidence interval (CI) 0.16–0.94) and Premofix® (HR: 0.37 (95% CI 0.15–0.90)) compared to controls (p < 0.05 for both). In patients receiving anticoagulation and/or DAPT undergoing CIED implantation, the use of Premofix® and stypro® significantly lowered the primary end point occurrence compared to control.”

GEN

ERA

L SU

RG

ERY

GC98


2014 GC Liu R, Li H, Yang J, Li H, Dai L, Gu C (2014): The experience of (stypro®) absorbable hemostatic collagen sponge in cardiac surgery using intraoperative hemostasis of sternum. Chinese Journal of Cardiovascular and Pulmonary Diseases, 2014 (05) [2014-09-26]. Article in Chinese, Abstract in English.

stypro®

Comment:

“To review their experience with stypro® absorbable hemostatic collagen sponge in the use of cardiac surgery for intraoperative hemostasis of the sternum Liu et al. (2014) divided 300 patients into three groups: Bone wax to complete the sternum bleeding; gelatine sponge group; and the group by blunt filling in the sternum bone marrow cavity. Results: The stypro® gelatine sponge group had obvious advantages regarding drainage, sternal dehiscence, wound fat liquefaction or infection, bleeding and secondary bone wax rejection. The authors came to the conclusion that stypro® hemostatic collagen sponge has a clear, simple application in the proposed clinical application in cardiac surgery and sternal surgical hemostasis.”


2003 GC Kirsch JJ, Staude G (2003): Mit stypro®-Tampons effektiv Blutungen stillen. [Stopping bleeding effectively with stypro® tampons.] Ambulante Chirurgie, August – September 2003, Volume 7, No. 36, Issue 4/2003: 38–39. Special Edition. Article in German, English translation available.

stypro®

Comment:

“The results of this study show that the stypro® tampon is suitable with respect to postoperative pain reduction, increased patient comfort and handling in peri- and postoperative hemostasis in ambulant surgery. An additional advantage is that the stypro® does not have to be removed but is simply excreted.”

OR

THO

PEDIC

S, TRA

UM

A & SPIN

E

99

SCIEN

TIFIC FU

ND

AM

ENTA

LS

SF99


2013 P Yazdi FK, Mostaghni E, Moghadam SA, Faghihi S, Monabati A, Amid R (2013): A comparison of the healing capabilities of vari-ous grafting materials in critical-size defects in guinea pig calvar-ia. Int J Oral Maxillofac Implants. 2013 Sep-Oct; 28 (5):1370-6. doi: 10.11607/jomi.2906. Article in English. Abstract in English available.

stypro®

Comment:

“To estimate the healing of 8-mm-diameter critical-size defects in guinea pig calvaria the efficacy of various bone grafting materials was tested. The mean bone formationwas 68.19% for autogenous bone, 66.96% for macroporous biphasic calcium phosphate (MBCP) gel, 18.79% for stypro®, and 10.61% for the empty control.”


2000 M Mertsching H, Merten HA, Bader A (2000): stypro® – A new and safe biomaterial for bone tissue engineering – without risk of endogenous retrovirus (PERV) infection. Poster presentation on the International Tissue Engineering Meeting, Innsbruck, Austria, May 18–20, 2000. Abstract in English.

stypro®

Comment:

“stypro® sponges carried no PERV sequences, which means that there is no infection risk combined with the implantation of stypro®.”

Notes Notizen

Notes Notizen

pine

1028

1111

12_0

1_20

21_0

03 ©

202

1 b

y cu

rasa

n A

G

DisclaimerThis document is intended exclusively for experts in the field, i. e. physicians in particular, and is expressly not for the information of laypersons.

The information on the products and/or procedures contained in this document is of a general nature and does not represent medical advice or recommendations. Since this information does not constitute any diagnostic or therapeutic statement with regard to any individual medical case, individual examination and advising of the respective patient are absolutely necessary and are not replaced by this document in whole or in part.

curasan AG Lindigstr. 4 | 63801 Kleinostheim | Germany

[email protected] | www.curasan.de

Tel.: +49 6027 / 40 900 - 0 | Fax: +49 6027 / 40 900 - 49

Documents

pedics Trauma entistry Orthopedics Den Dentistry Orthop